

APPENDICE 1/APPENDIX 1  
TABELLE RIEPILOGATIVE  
SUMMARY TABLES

APPENDICE 2/APPENDIX 2  
LA RETE DEI REGISTRI AIRTUM  
THE NETWORK OF THE AIRTUM CANCER REGISTRIES

APPENDICI

e&o

CANCER SITE																		
Year	MALE						FEMALE						MALE & FEMALE					
	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>HEAD AND NECK</b>																		
1	14050	79.2	81.3	0.4	81.3	0.4	3462	77.3	79.3	0.7	79.3	0.7	17512	78.8	80.9	0.3	80.9	0.3
2	11107	65.5	69.0	0.4	69.1	0.4	2666	64.0	66.9	0.9	67.3	0.9	13773	65.2	68.6	0.4	68.7	0.4
3	9176	58.0	62.6	0.5	62.8	0.5	2200	57.9	61.7	0.9	62.4	0.9	11376	58.0	62.4	0.4	62.8	0.4
4	8097	53.0	58.8	0.5	59.1	0.5	1984	53.3	58.1	0.9	59.1	0.9	10081	53.1	58.6	0.4	59.1	0.4
5	7389	48.9	55.8	0.5	56.2	0.5	1827	50.7	56.3	1.0	57.8	1.0	9216	49.3	55.9	0.4	56.5	0.4
<b>SALIVARY GLANDS</b>																		
1	679	76.9	79.9	1.7	79.9	1.7	466	80.5	83.0	1.9	83.0	1.9	1145	78.3	81.2	1.3	81.2	1.3
2	521	63.4	68.2	2.0	68.6	2.0	375	70.8	74.7	2.2	75.3	2.2	896	66.4	70.8	1.5	71.4	1.5
3	430	57.2	63.3	2.1	64.4	2.1	329	64.8	69.7	2.4	71.1	2.4	759	60.3	65.9	1.6	67.2	1.6
4	388	52.4	59.6	2.2	61.4	2.2	300	61.3	67.3	2.5	69.5	2.6	688	56.0	62.7	1.6	64.7	1.7
5	355	48.2	56.4	2.3	58.8	2.4	283	58.5	65.5	2.6	68.4	2.7	638	52.4	60.1	1.7	62.8	1.8
<b>ESOPHAGUS</b>																		
1	3170	37.4	38.7	0.9	38.7	0.9	1005	35.0	36.4	1.6	36.4	1.6	4175	36.8	38.1	0.8	38.1	0.8
2	1183	19.8	21.0	0.8	21.2	0.8	350	19.5	20.8	1.3	21.1	1.4	1533	19.7	20.9	0.7	21.1	0.7
3	623	14.4	15.6	0.7	16.0	0.7	194	14.6	15.8	1.2	16.4	1.3	817	14.4	15.7	0.6	16.1	0.6
4	454	11.3	12.5	0.6	13.0	0.6	144	11.7	13.0	1.1	13.8	1.2	598	11.4	12.6	0.5	13.2	0.6
5	354	9.9	11.3	0.6	11.9	0.6	116	10.3	11.6	1.1	12.6	1.2	470	10.0	11.4	0.5	12.0	0.6
<b>STOMACH</b>																		
1	15502	48.6	51.0	0.4	51.0	0.4	11117	49.3	51.6	0.5	51.6	0.5	26619	48.9	51.2	0.3	51.2	0.3
2	7518	35.3	38.5	0.4	38.9	0.4	5468	37.1	40.1	0.5	40.6	0.5	12986	36.0	39.2	0.3	39.6	0.3
3	5454	28.8	32.7	0.4	33.4	0.4	4099	31.8	35.5	0.5	36.5	0.5	9553	30.1	33.8	0.3	34.7	0.3
4	4447	25.2	29.7	0.4	30.7	0.4	3504	28.3	32.7	0.5	34.2	0.5	7951	26.5	31.0	0.3	32.2	0.3
5	3882	22.8	28.0	0.4	29.3	0.4	3111	26.0	31.1	0.5	33.1	0.5	6993	24.2	29.3	0.3	30.9	0.3
<b>SMALL INTESTINE</b>																		
1	853	65.1	67.4	1.7	67.4	1.7	707	65.6	67.7	1.8	67.7	1.8	1560	65.3	67.6	1.2	67.6	1.2
2	555	55.1	58.8	1.8	59.2	1.8	458	54.6	57.5	2.0	58.2	2.0	1013	54.9	58.2	1.3	58.8	1.4
3	470	49.7	54.6	1.9	55.5	1.9	381	49.4	53.2	2.0	54.5	2.1	851	49.6	54.0	1.4	55.0	1.4
4	424	45.3	51.2	1.9	52.5	2.0	344	46.1	50.8	2.1	52.6	2.1	768	45.6	51.0	1.4	52.5	1.5
5	386	41.3	48.2	2.0	49.8	2.1	319	43.5	48.9	2.1	51.4	2.2	705	42.2	48.5	1.5	50.5	1.5
<b>COLON</b>																		
1	26218	75.4	78.7	0.3	78.7	0.3	23246	74.3	76.9	0.3	76.9	0.3	49464	74.9	77.9	0.2	77.9	0.2
2	19710	64.7	70.2	0.3	70.5	0.3	17243	64.2	68.4	0.3	68.8	0.3	36953	64.5	69.4	0.2	69.7	0.2
3	16891	57.2	64.6	0.3	65.2	0.3	14857	57.5	63.2	0.4	64.1	0.4	31748	57.4	64.0	0.2	64.6	0.3
4	14892	51.7	60.9	0.4	61.7	0.4	13305	53.3	60.4	0.4	61.7	0.4	28197	52.4	60.7	0.3	61.7	0.3
5	13434	47.4	58.4	0.4	59.3	0.4	12295	49.6	58.1	0.4	59.8	0.4	25729	48.4	58.3	0.3	59.5	0.3
<b>RECTUM</b>																		
1	12644	78.1	81.2	0.4	81.2	0.4	9740	77.2	79.8	0.4	79.8	0.4	22384	77.7	80.6	0.3	80.6	0.3
2	9851	66.2	71.3	0.5	71.6	0.5	7514	65.8	69.9	0.5	70.3	0.5	17365	66.0	70.7	0.3	71.0	0.3
3	8337	57.8	64.6	0.5	65.2	0.5	6392	58.0	63.2	0.5	64.0	0.6	14729	57.9	64.0	0.4	64.7	0.4
4	7265	51.3	59.5	0.5	60.4	0.5	5617	52.6	58.8	0.6	60.2	0.6	12882	51.9	59.2	0.4	60.3	0.4
5	6439	46.7	56.3	0.5	57.4	0.6	5079	48.4	55.7	0.6	57.5	0.6	11518	47.4	56.0	0.4	57.4	0.4
<b>COLON RECTUM</b>																		
1	38862	76.3	79.5	0.2	79.5	0.2	32986	75.2	77.8	0.2	77.8	0.2	71848	75.8	78.7	0.2	78.7	0.2
2	29561	65.2	70.6	0.3	70.9	0.3	24757	64.7	68.8	0.3	69.2	0.3	54318	65.0	69.8	0.2	70.1	0.2
3	25228	57.4	64.6	0.3	65.2	0.3	21249	57.7	63.2	0.3	64.1	0.3	46477	57.5	64.0	0.2	64.7	0.2
4	22157	51.6	60.5	0.3	61.3	0.3	18922	53.1	59.9	0.3	61.2	0.3	41079	52.3	60.2	0.2	61.2	0.2
5	19873	47.2	57.7	0.3	58.7	0.3	17374	49.3	57.4	0.3	59.1	0.3	37247	48.1	57.6	0.2	58.9	0.2
<b>LIVER</b>																		
1	12153	44.6	46.2	0.5	46.2	0.5	5573	39.0	40.5	0.7	40.5	0.7	17726	42.9	44.4	0.4	44.4	0.4
2	5406	29.9	31.9	0.4	32.1	0.4	2170	25.5	27.1	0.6	27.4	0.6	7576	28.5	30.4	0.4	30.6	0.4
3	3605	21.9	24.1	0.4	24.4	0.4	1409	18.7	20.3	0.6	20.9	0.6	5014	20.9	22.9	0.3	23.3	0.3
4	2634	16.4	18.7	0.4	19.1	0.4	1031	13.2	14.7	0.5	15.4	0.5	3665	15.4	17.4	0.3	18.0	0.3
5	1966	12.6	14.7	0.4	15.2	0.4	725	10.5	12.0	0.5	12.8	0.5	2691	11.9	13.9	0.3	14.5	0.3
<b>BILIARY TRACT</b>																		
1	2950	35.3	37.1	0.9	37.1	0.9	4324	29.5	30.8	0.7	30.8	0.7	7274	31.9	33.3	0.6	33.3	0.6
2	1038	21.9	23.9	0.8	24.2	0.8	1267	18.4	19.8	0.6	20.1	0.6	2305	19.9	21.5	0.5	21.8	0.5
3	643	15.8	17.9	0.8	18.4	0.8	788	14.2	15.7	0.6	16.2	0.6	1431	14.8	16.6	0.5	17.1	0.5
4	461	13.1	15.5	0.7	16.1	0.8	603	12.1	13.8	0.6	14.5	0.6	1064	12.5	14.5	0.5	15.2	0.5
5	383	11.6	14.1	0.7	15.0	0.8	512	10.5	12.4	0.6	13.3	0.6	895	10.9	13.1	0.4	13.9	0.5

Table 1. Number of initial records, observed survival (OS), relative survival (RS) and standard error (SE) by year from diagnosis, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Year	MALE						FEMALE						MALE & FEMALE					
	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>PANCREAS</b>																		
1	7629	22.1	23.1	0.5	23.1	0.5	8141	21.1	22.0	0.5	22.0	0.5	15770	21.6	22.5	0.3	22.5	0.3
2	1683	10.5	11.3	0.4	11.4	0.4	1705	10.0	10.7	0.4	10.9	0.4	3388	10.2	11.0	0.3	11.2	0.3
3	797	6.7	7.4	0.3	7.6	0.3	809	6.8	7.5	0.3	7.7	0.3	1606	6.7	7.4	0.2	7.7	0.2
4	506	5.1	5.9	0.3	6.1	0.3	549	5.5	6.2	0.3	6.5	0.3	1055	5.3	6.0	0.2	6.3	0.2
5	387	4.4	5.2	0.3	5.5	0.3	439	4.8	5.5	0.3	6.0	0.3	826	4.6	5.4	0.2	5.7	0.2
<b>LARYNX</b>																		
1	6958	87.2	89.7	0.4	89.7	0.4	709	84.4	86.3	1.4	86.3	1.4	7667	87.0	89.4	0.4	89.4	0.4
2	6060	76.7	81.1	0.5	81.2	0.5	594	74.7	78.0	1.7	78.2	1.7	6654	76.5	80.8	0.5	80.9	0.5
3	5315	69.7	76.0	0.6	76.2	0.6	524	68.6	73.1	1.9	73.5	1.9	5839	69.6	75.7	0.6	75.9	0.6
4	4826	64.6	72.5	0.6	72.9	0.6	481	63.9	69.5	2.0	70.1	2.0	5307	64.5	72.2	0.6	72.6	0.6
5	4466	60.2	69.8	0.7	70.2	0.7	448	61.5	68.3	2.0	69.2	2.1	4914	60.4	69.6	0.7	70.1	0.7
<b>LUNG</b>																		
1	47499	37.2	38.6	0.2	38.6	0.2	13625	41.1	42.2	0.4	42.2	0.4	61124	38.1	39.4	0.2	39.4	0.2
2	17585	20.6	22.2	0.2	22.3	0.2	5568	24.7	25.9	0.4	26.2	0.4	23153	21.6	23.0	0.2	23.2	0.2
3	9735	14.8	16.4	0.2	16.7	0.2	3341	19.0	20.3	0.4	20.7	0.4	13076	15.7	17.3	0.2	17.6	0.2
4	6969	12.1	13.8	0.2	14.2	0.2	2558	15.7	17.1	0.3	17.7	0.4	9527	12.9	14.6	0.2	15.0	0.2
5	5676	10.4	12.3	0.2	12.8	0.2	2106	13.9	15.5	0.3	16.2	0.3	7782	11.2	13.0	0.2	13.6	0.2
<b>BONE</b>																		
1	460	78.0	79.5	2.0	79.5	2.0	348	75	76.4	2.4	76.4	2.4	808	76.7	78.2	1.5	78.2	1.5
2	356	65.0	67.2	2.3	67.6	2.3	261	67.5	69.6	2.6	70.2	2.6	617	66.1	68.3	1.7	68.7	1.7
3	294	57.0	59.8	2.4	60.5	2.5	234	62.0	64.7	2.7	65.7	2.8	528	59.2	61.9	1.8	62.8	1.8
4	258	52.4	55.7	2.5	56.7	2.5	213	56.5	59.5	2.8	61.0	2.9	471	54.2	57.3	1.9	58.6	1.9
5	236	48.4	52.1	2.5	53.5	2.6	193	54.2	57.7	2.9	59.8	3.0	429	50.9	54.5	1.9	56.2	2.0
<b>SKIN MELANOMA</b>																		
1	6242	93.1	95.3	0.3	95.3	0.3	6360	95.1	96.6	0.3	96.6	0.3	12602	94.1	95.9	0.2	95.9	0.2
2	5806	85.7	89.6	0.5	89.7	0.5	6032	91.0	93.8	0.4	93.9	0.4	11838	88.4	91.7	0.3	91.8	0.3
3	5324	80.1	85.6	0.5	85.9	0.5	5758	87.5	91.4	0.4	91.7	0.4	11082	83.8	88.6	0.3	88.8	0.3
4	4969	76.1	83.1	0.6	83.6	0.6	5523	84.8	89.9	0.5	90.4	0.5	10492	80.5	86.6	0.4	87.1	0.4
5	4706	72.6	81.1	0.6	81.7	0.6	5336	82.3	88.4	0.5	89.1	0.5	10042	77.5	84.8	0.4	85.5	0.4
<b>MESOTHELIOMA</b>																		
1	1925	42.0	43.7	1.2	43.7	1.2	679	44.2	45.3	2.0	45.3	2.0	2604	42.6	44.1	1.0	44.1	1.0
2	808	19.2	20.6	1.0	20.8	1.0	297	20.5	21.5	1.6	21.6	1.6	1105	19.6	20.9	0.8	21.0	0.8
3	370	12.1	13.3	0.8	13.6	0.8	137	12.0	12.8	1.3	13.0	1.4	507	12.0	13.2	0.7	13.4	0.7
4	231	8.4	9.6	0.7	9.9	0.7	80	9.1	9.9	1.2	10.2	1.2	311	8.6	9.7	0.6	10.0	0.6
5	160	6.1	7.2	0.7	7.5	0.7	61	7.1	7.8	1.1	8.2	1.2	221	6.3	7.3	0.6	7.7	0.6
<b>KAPOSI SARCOMA</b>																		
1	799	83.0	86.0	1.4	86.0	1.4	319	90.9	95.1	1.7	95.1	1.7	1118	85.2	88.6	1.1	88.6	1.1
2	661	77.9	83.8	1.6	83.9	1.6	290	84.6	93.0	2.2	92.8	2.2	951	79.8	86.4	1.3	86.4	1.3
3	620	75.3	84.0	1.7	84.1	1.7	269	81.2	93.7	2.5	93.5	2.5	889	77.0	86.8	1.4	86.7	1.4
4	597	72.4	84.0	1.8	84.0	1.8	258	76.8	93.5	2.9	93.0	2.9	855	73.6	86.7	1.6	86.5	1.6
5	567	68.8	82.9	2.0	82.9	2.0	244	70.6	90.8	3.3	90.1	3.3	811	69.3	85.2	1.7	84.9	1.7
<b>SOFT TISSUE</b>																		
1	1418	77.6	79.9	1.1	79.9	1.1	1204	79.1	80.8	1.2	80.8	1.2	2622	78.3	80.3	0.8	80.3	0.8
2	1097	66.8	70.5	1.3	70.7	1.3	949	69.3	71.9	1.4	72.2	1.4	2046	67.9	71.1	1.0	71.4	1.0
3	942	61.1	66.0	1.4	66.6	1.4	828	62.9	66.3	1.5	67.0	1.5	1770	61.9	66.2	1.0	66.8	1.0
4	859	56.5	62.6	1.5	63.5	1.5	747	58.7	62.9	1.5	64.0	1.6	1606	57.6	62.7	1.1	63.8	1.1
5	794	53.7	60.9	1.5	62.3	1.5	693	56.4	61.3	1.6	62.9	1.6	1487	55.0	61.0	1.1	62.6	1.1
<b>BREAST</b>																		
1							76708	95.2	96.9	0.1	96.9	0.1						
2							72913	90.9	94.1	0.1	94.2	0.1						
3							69457	86.7	91.3	0.1	91.5	0.1						
4							66092	82.8	88.7	0.1	89.1	0.1						
5							62991	79.3	86.5	0.2	87.0	0.2						
<b>CERVIX UTERI</b>																		
1							4268	85.8	87.0	0.5	87.0	0.5						
2							3644	75.0	77.0	0.7	77.3	0.7						
3							3172	69.5	72.0	0.7	72.6	0.7						
4							2922	66.0	69.2	0.8	70.1	0.8						
5							2765	63.4	67.1	0.8	68.4	0.8						

Table 1. Number of initial records, observed survival (OS), relative survival (RS) and standard error (SE) by year from diagnosis, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Year	MALE						FEMALE						MALE & FEMALE					
	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>CORPUS UTERI</b>																		
1							11511	90.1	91.8	0.3	91.8	0.3						
2							10357	83.3	86.3	0.4	86.4	0.4						
3							9553	77.8	81.9	0.4	82.4	0.4						
4							8910	74.0	79.3	0.4	80.1	0.4						
5							8457	71.2	77.6	0.5	78.8	0.5						
<b>OVARY</b>																		
1							8274	70.5	72.0	0.5	72.0	0.5						
2							5811	57.2	59.2	0.6	59.8	0.6						
3							4708	47.9	50.3	0.6	51.3	0.6						
4							3928	42.0	44.6	0.6	46.0	0.6						
5							3429	37.8	40.6	0.6	42.5	0.6						
<b>PROSTATE</b>																		
1	58100	92.1	96.0	0.1	96.0	0.1												
2	53433	86.0	93.3	0.2	93.6	0.2												
3	49829	80.7	91.4	0.2	91.9	0.2												
4	46731	76.1	89.9	0.2	90.7	0.2												
5	43964	71.6	88.5	0.2	89.7	0.2												
<b>TESTIS</b>																		
1	2618	96.9	97.3	0.3	97.3	0.3												
2	2525	95.3	96.0	0.4	96.1	0.4												
3	2472	94.2	95.3	0.5	95.4	0.5												
4	2434	93.8	95.2	0.5	95.3	0.5												
5	2414	93.2	94.9	0.5	95.2	0.5												
<b>KIDNEY</b>																		
1	9271	79.3	81.6	0.4	81.6	0.4	5182	79.1	81.1	0.6	81.1	0.6	14453	79.2	81.5	0.3	81.5	0.3
2	7326	71.7	75.8	0.5	76.1	0.5	4095	71.9	75.3	0.7	75.6	0.7	11421	71.7	75.6	0.4	75.9	0.4
3	6615	66.8	72.6	0.5	73.3	0.5	3716	67.4	72.1	0.7	72.8	0.7	10331	67.0	72.4	0.4	73.1	0.4
4	6160	62.7	70.0	0.6	71.0	0.6	3479	63.8	69.7	0.7	70.9	0.7	9639	63.1	69.9	0.4	71.0	0.5
5	5773	59.3	68.1	0.6	69.5	0.6	3286	60.9	68.0	0.8	69.8	0.8	9059	59.9	68.1	0.5	69.6	0.5
<b>URINARY TRACT</b>																		
1	1862	74.2	77.4	1.1	77.4	1.1	858	70.2	72.8	1.6	72.8	1.6	2720	72.9	76.0	0.9	76.0	0.9
2	1379	62.0	67.4	1.2	67.8	1.2	602	56.3	60.4	1.8	60.7	1.8	1981	60.2	65.2	1.0	65.5	1.0
3	1152	56.3	63.6	1.3	64.4	1.3	480	49.9	55.5	1.9	56.2	1.9	1632	54.3	61.0	1.1	61.8	1.1
4	1046	52.0	61.0	1.4	62.4	1.4	425	45.9	52.9	2.0	53.9	2.0	1471	50.1	58.4	1.1	59.7	1.1
5	965	48.4	59.1	1.4	60.9	1.5	390	43.3	51.8	2.0	53.1	2.1	1355	46.8	56.7	1.2	58.4	1.2
<b>URINARY BLADDER</b>																		
1	30729	86.5	90.1	0.2	90.1	0.2	7517	81.6	84.6	0.5	84.6	0.5	38246	85.5	89.0	0.2	89.0	0.2
2	26505	78.3	84.9	0.3	85.2	0.3	6113	73.4	78.5	0.5	79.0	0.5	32618	77.3	83.6	0.2	83.9	0.2
3	23956	72.1	81.4	0.3	81.9	0.3	5484	68.9	76.0	0.6	77.1	0.6	29440	71.5	80.3	0.3	81.0	0.3
4	21996	67.3	79.1	0.3	80.0	0.3	5138	64.4	73.2	0.6	75.0	0.6	27134	66.7	77.9	0.3	79.0	0.3
5	20471	62.6	76.6	0.3	78.0	0.3	4783	61.0	71.6	0.7	74.0	0.7	25254	62.2	75.7	0.3	77.2	0.3
<b>CHOROID MELANOMA</b>																		
1	117	90.6	93.5	2.8	93.5	2.8	100	90	93.3	3.1	93.3	3.1	217	90.3	93.4	2.1	93.4	2.1
2	105	83.7	89.0	3.6	89.2	3.7	90	85	90.8	3.8	91.4	3.8	195	84.3	89.8	2.6	90.2	2.6
3	97	76.8	84.3	4.3	84.6	4.3	85	81	89.2	4.3	90.4	4.4	182	78.7	86.6	3.1	87.3	3.1
4	89	74.2	84.1	4.6	84.6	4.6	81	74	84.0	5.0	85.8	5.1	170	74.1	84.0	3.4	85.2	3.4
5	86	66.5	78.1	5.2	78.7	5.3	74	71.7	84.0	5.3	86.5	5.5	160	68.9	80.8	3.7	82.3	3.8
<b>BRAIN AND CENTRAL NERVOUS SYSTEM</b>																		
1	4313	40.8	41.9	0.8	41.9	0.8	3762	39.1	39.9	0.8	39.9	0.8	8075	40.0	41.0	0.6	41.0	0.6
2	1754	23.4	24.2	0.7	24.6	0.7	1463	24.4	25.1	0.7	25.5	0.7	3217	23.8	24.7	0.5	25.0	0.5
3	994	18.9	19.9	0.6	20.4	0.6	907	20.0	20.9	0.7	21.4	0.7	1901	19.4	20.3	0.5	20.9	0.5
4	804	16.4	17.4	0.6	18.2	0.6	744	17.9	18.8	0.7	19.6	0.7	1548	17.1	18.0	0.4	18.9	0.5
5	692	14.8	15.8	0.6	16.9	0.6	661	16.5	17.5	0.6	18.6	0.7	1353	15.6	16.6	0.4	17.7	0.5
<b>THYROID</b>																		
1	2586	91.6	92.9	0.6	92.9	0.6	8287	95.8	96.5	0.2	96.5	0.2	10873	94.8	95.6	0.2	95.6	0.2
2	2361	89.6	91.9	0.6	92.1	0.6	7913	94.6	95.8	0.3	96.0	0.3	10274	93.4	94.9	0.2	95.1	0.2
3	2301	87.9	91.3	0.7	91.7	0.7	7796	93.7	95.4	0.3	95.8	0.3	10097	92.3	94.4	0.3	94.8	0.3
4	2251	86.3	90.7	0.7	91.4	0.7	7687	92.9	95.2	0.3	95.8	0.3	9938	91.3	94.1	0.3	94.7	0.3
5	2203	84.5	90.0	0.8	90.9	0.8	7604	91.9	94.8	0.3	95.6	0.3	9807	90.1	93.7	0.3	94.5	0.3

Table 1. Number of initial records, observed survival (OS), relative survival (RS) and standard error (SE) by year from diagnosis, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Year	MALE						FEMALE						MALE & FEMALE					
	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	No.	OS%	RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>HODGKIN LYMPHOMA</b>																		
1	1624	91.9	92.7	0.7	92.7	0.7	1385	92.0	92.7	0.7	92.7	0.7	3009	91.9	92.7	0.5	92.7	0.5
2	1485	86.8	88.3	0.9	88.5	0.9	1269	88.9	90.0	0.9	90.3	0.9	2754	87.8	89.1	0.6	89.3	0.6
3	1397	83.3	85.3	1.0	85.8	1.0	1221	86.4	88.0	0.9	88.5	0.9	2618	84.7	86.5	0.7	87.0	0.7
4	1335	81.3	83.8	1.0	84.6	1.0	1181	84.5	86.4	1.0	87.2	1.0	2516	82.8	85.0	0.7	85.8	0.7
5	1298	79.3	82.3	1.1	83.4	1.1	1150	82.8	85.1	1.1	86.2	1.1	2448	80.9	83.6	0.7	84.7	0.8
<b>NON HODGKIN LYMPHOMA</b>																		
1	9918	74.6	76.9	0.5	76.9	0.5	9043	73.2	75.1	0.5	75.1	0.5	18961	73.9	76.0	0.3	76.0	0.3
2	7381	65.9	69.8	0.5	70.1	0.5	6599	65.5	68.5	0.5	68.9	0.5	13980	65.7	69.2	0.4	69.5	0.4
3	6507	60.6	65.8	0.5	66.6	0.5	5895	60.7	64.8	0.5	65.7	0.6	12402	60.7	65.3	0.4	66.2	0.4
4	5979	56.8	63.3	0.6	64.4	0.6	5455	57.1	62.1	0.6	63.5	0.6	11434	56.9	62.7	0.4	64.0	0.4
5	5585	53.4	61.0	0.6	62.6	0.6	5111	53.7	59.6	0.6	61.5	0.6	10696	53.5	60.3	0.4	62.1	0.4
<b>MYELOMA</b>																		
1	3694	73.6	76.8	0.8	76.8	0.8	3662	72.8	75.2	0.8	75.2	0.8	7356	73.2	76.0	0.5	76.0	0.5
2	2711	59.9	64.8	0.9	65.1	0.9	2656	58.9	62.5	0.9	62.9	0.9	5367	59.4	63.6	0.6	64.0	0.6
3	2201	50.6	56.7	0.9	57.6	0.9	2146	49.1	53.5	0.9	54.3	0.9	4347	49.9	55.1	0.6	55.9	0.7
4	1856	42.6	49.3	0.9	50.6	1.0	1787	41.4	46.3	0.9	47.5	0.9	3643	42.0	47.8	0.7	49.0	0.7
5	1553	36.2	43.4	1.0	45.1	1.0	1504	35.4	40.6	0.9	42.2	1.0	3057	35.8	42.0	0.7	43.6	0.7
<b>ACUTE LYMPHATIC LEUKAEMIA</b>																		
1	375	53.9	55.1	2.6	55.1	2.6	332	56.9	57.8	2.8	57.8	2.8	707	55.3	56.4	1.9	56.4	1.9
2	199	33.8	35.0	2.5	35.4	2.6	188	39.6	40.6	2.8	41.0	2.8	387	36.6	37.7	1.9	38.1	1.9
3	125	26.5	27.8	2.4	28.4	2.5	131	31.5	32.5	2.6	33.1	2.7	256	28.9	30.0	1.8	30.7	1.8
4	98	23.5	24.8	2.3	25.8	2.4	104	29.3	30.5	2.6	31.4	2.7	202	26.3	27.5	1.7	28.5	1.8
5	85	22.3	23.8	2.3	25.0	2.4	97	27.0	28.3	2.6	29.5	2.7	182	24.5	25.9	1.7	27.2	1.8
<b>CHRONIC LYMPHATIC LEUKAEMIA</b>																		
1	2672	84.7	88.5	0.7	88.6	0.7	1934	84.4	87.9	0.9	87.9	0.9	4606	84.6	88.3	0.6	88.3	0.6
2	2258	76.9	83.7	0.9	84.1	0.9	1625	76.7	82.7	1.0	83.2	1.0	3883	76.8	83.3	0.7	83.7	0.7
3	2046	69.2	78.3	1.0	79.2	1.0	1474	69.1	77.2	1.2	78.2	1.2	3520	69.1	77.8	0.8	78.8	0.8
4	1839	62.5	73.7	1.1	75.1	1.1	1324	63.3	73.2	1.3	74.9	1.3	3163	62.9	73.5	0.8	75.0	0.9
5	1659	56.4	69.2	1.2	71.1	1.2	1209	57.0	68.1	1.4	70.5	1.4	2868	56.7	68.7	0.9	70.9	0.9
<b>ACUTE MYELOID LEUKAEMIA</b>																		
1	2087	33.6	34.9	1.1	34.9	1.1	1927	33.5	34.5	1.1	34.5	1.1	4014	33.6	34.7	0.8	34.7	0.8
2	699	20.3	21.5	0.9	21.9	1.0	645	23.5	24.4	1.0	24.9	1.0	1344	21.8	22.9	0.7	23.4	0.7
3	420	16.4	17.7	0.9	18.6	0.9	451	19.3	20.2	0.9	21.1	1.0	871	17.8	19.0	0.6	19.8	0.7
4	340	15.3	16.7	0.9	18.1	0.9	367	17.5	18.5	0.9	19.7	1.0	707	16.4	17.6	0.6	18.9	0.7
5	317	14.0	15.5	0.8	17.2	0.9	332	16.7	17.8	0.9	19.4	1.0	649	15.3	16.6	0.6	18.3	0.7
<b>CHRONIC MYELOID LEUKAEMIA</b>																		
1	1044	72.5	75.5	1.4	75.5	1.4	810	72.3	74.8	1.6	74.8	1.6	1854	72.4	75.2	1.1	75.2	1.1
2	753	56.3	60.7	1.7	61.2	1.7	585	61.8	65.5	1.8	66.1	1.8	1338	58.7	62.8	1.2	63.4	1.2
3	584	49.0	54.4	1.7	55.6	1.8	499	55.0	59.7	1.9	60.9	1.9	1083	51.6	56.7	1.3	57.9	1.3
4	507	44.7	51.1	1.8	53.0	1.8	444	50.9	56.5	2.0	58.4	2.0	951	47.4	53.5	1.3	55.4	1.4
5	460	40.0	47.0	1.8	49.7	1.9	408	45.9	52.0	2.0	54.6	2.1	868	42.6	49.2	1.3	51.9	1.4
<b>ALL LEUKAEMIAS</b>																		
1	7095	63.0	65.7	0.6	65.7	0.6	5701	59.2	61.2	0.7	61.2	0.7	12796	61.3	63.7	0.4	63.7	0.4
2	4455	51.7	55.6	0.6	56.1	0.6	3361	49.5	52.6	0.7	53.1	0.7	7816	50.7	54.3	0.5	54.8	0.5
3	3644	45.6	50.7	0.7	51.7	0.7	2809	43.4	47.4	0.7	48.3	0.7	6453	44.6	49.2	0.5	50.2	0.5
4	3213	41.6	47.7	0.7	49.2	0.7	2454	39.9	44.7	0.7	46.1	0.8	5667	40.8	46.4	0.5	47.8	0.5
5	2920	37.7	44.7	0.7	46.7	0.7	2246	36.5	41.9	0.7	43.7	0.8	5166	37.2	43.4	0.5	45.4	0.5
<b>ALL BUT SKIN, NON MELANOMA</b>																		
1	298749	68.1	70.8	0.1	70.8	0.1	250088	74.7	76.7	0.1	76.7	0.1	548837	71.1	73.5	0.1	73.5	0.1
2	202966	57.3	61.6	0.1	61.9	0.1	186423	66.4	69.5	0.1	70.0	0.1	389389	61.4	65.3	0.1	65.7	0.1
3	170418	51.3	57.1	0.1	57.7	0.1	165262	61.3	65.5	0.1	66.5	0.1	335680	55.8	61.0	0.1	61.8	0.1
4	152232	47.1	54.4	0.1	55.3	0.1	152146	57.5	62.7	0.1	64.2	0.1	304378	51.8	58.2	0.1	59.5	0.1
5	139467	43.7	52.3	0.1	53.5	0.1	142437	54.5	60.6	0.1	62.7	0.1	281904	48.6	56.1	0.1	57.8	0.1
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>																		
1	268020	66.0	68.6	0.1	68.6	0.1	242571	74.5	76.5	0.1	76.5	0.1	510591	70.1	72.3	0.1	72.3	0.1
2	176461	54.9	59.0	0.1	59.3	0.1	180310	66.2	69.3	0.1	69.7	0.1	356771	60.2	63.9	0.1	64.3	0.1
3	146462	48.9	54.4	0.1	55.0	0.1	159778	61.0	65.1	0.1	66.1	0.1	306240	54.7	59.5	0.1	60.4	0.1
4	130236	44.8	51.6	0.1	52.5	0.1	147008	57.3	62.4	0.1	63.9	0.1	277244	50.7	56.8	0.1	58.0	0.1
5	118996	41.5	49.5	0.1	50.7	0.1	137654	54.3	60.3	0.1	62.3	0.1	256650	47.6	54.7	0.1	56.4	0.1

Table 1. Number of initial records, observed survival (OS), relative survival (RS) and standard error (SE) by year from diagnosis, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CANCER SITE																		
Age	MALE						FEMALE						MALE & FEMALE					
	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %
<b>HEAD AND NECK</b>																		
15-44	394	61.1	61.6	2.0	61.6	2.0	183	70.7	71.0	2.9	71.0	2.9	577	63.9	64.3	1.6	64.3	1.6
45-54	1258	55.9	57.1	1.1	57.1	1.1	309	62.5	63.2	2.2	63.2	2.2	1567	57.1	58.2	1.0	58.2	1.0
55-64	2459	54.4	57.5	0.8	57.5	0.8	473	61.4	62.9	1.8	62.9	1.8	2932	55.4	58.3	0.7	58.3	0.7
65-74	2259	48.6	56.1	0.9	56.1	0.9	512	55.9	59.9	1.8	59.9	1.8	2771	49.8	56.7	0.8	56.8	0.8
75+	1019	32.6	49.9	1.4	50.5	1.4	350	29.4	41.2	2.0	42.6	2.0	1369	31.6	47.4	1.1	48.1	1.2
<b>SALIVARY GLANDS</b>																		
15-44	60	92.3	92.9	3.3	92.9	3.3	54	90.1	90.4	3.8	90.4	3.8	114	91.3	91.7	2.5	91.7	2.5
45-54	70	68.8	70.3	5.0	70.3	5.0	56	90.3	91.3	3.8	91.4	3.8	126	77.5	78.8	3.5	78.9	3.5
55-64	92	63.2	66.7	4.5	66.7	4.5	54	70.1	71.9	5.4	71.9	5.4	146	65.9	68.7	3.5	68.7	3.5
65-74	79	41.9	48.7	4.4	48.7	4.4	72	63.5	68.7	5.1	68.6	5.1	151	50.0	56.3	3.4	56.5	3.4
75+	54	22.0	36.2	4.7	37.4	4.8	47	25.2	36.9	5.1	39.1	5.4	101	23.4	36.4	3.4	38.2	3.6
<b>OESOPHAGUS</b>																		
15-44	16	18.5	18.6	4.4	18.6	4.4	4	-	-	-	-	-	20	18.6	18.7	3.9	18.7	3.9
45-54	65	17.4	17.8	2.2	17.8	2.2	14	-	-	-	-	-	79	18.0	18.4	2.0	18.4	2.0
55-64	128	12.9	13.6	1.2	13.6	1.2	35	18.4	18.8	3.2	18.9	3.2	163	13.7	14.4	1.1	14.4	1.1
65-74	118	10.4	12.0	1.1	12.1	1.1	45	14.6	15.7	2.3	15.7	2.3	163	11.3	12.8	1.0	12.9	1.0
75+	27	2.2	3.5	0.8	3.6	0.9	18	3.2	4.3	1.1	4.8	1.2	45	2.6	3.8	0.7	4.1	0.7
<b>STOMACH</b>																		
15-44	163	41.6	41.9	2.6	41.9	2.6	152	43.3	43.4	2.7	43.4	2.7	315	42.4	42.6	1.9	42.6	1.9
45-54	407	40.2	41.1	1.6	41.1	1.6	272	44.6	45.1	2.1	45.1	2.1	679	41.8	42.6	1.3	42.6	1.3
55-64	965	33.9	35.9	1.0	35.9	1.0	560	40.7	41.8	1.4	41.8	1.4	1525	36.1	37.8	0.8	37.8	0.8
65-74	1431	25.3	29.3	0.7	29.4	0.7	984	34.4	37.0	1.0	37.0	1.0	2415	28.4	32.0	0.6	32.1	0.6
75+	916	12.3	19.7	0.7	20.5	0.7	1143	16.6	23.7	0.7	25.3	0.7	2059	14.4	21.7	0.5	23.0	0.5
<b>SMALL INTESTINE</b>																		
15-44	33	70.9	71.4	6.8	71.4	6.8	41	78.8	79.1	5.7	79.1	5.7	74	75.1	75.5	4.4	75.5	4.4
45-54	56	57.8	59.1	5.3	59.1	5.3	45	65.5	66.3	6.1	66.3	6.1	101	61.0	62.1	4.0	62.1	4.0
55-64	104	51.8	54.7	4.0	54.7	4.0	76	63.7	65.4	4.5	65.4	4.5	180	56.6	59.0	3.0	59.1	3.0
65-74	131	43.9	50.4	3.5	50.6	3.5	93	44.9	48.3	3.9	48.4	3.9	224	44.3	49.5	2.6	49.6	2.6
75+	62	20.4	32.0	4.0	32.7	4.0	64	21.1	30.2	3.6	31.7	3.8	126	20.8	31.1	2.7	32.2	2.8
<b>COLON</b>																		
15-44	378	63.1	63.5	2.0	63.5	2.0	384	62.7	63.0	2.0	63.0	2.0	762	62.9	63.2	1.4	63.2	1.4
45-54	1169	61.5	62.8	1.2	62.8	1.2	1107	63.7	64.4	1.2	64.4	1.2	2276	62.5	63.6	0.8	63.6	0.8
55-64	3186	60.7	64.2	0.7	64.2	0.7	2633	66.1	67.9	0.8	67.9	0.8	5819	63.1	65.8	0.5	65.8	0.5
65-74	5012	51.6	59.8	0.6	59.9	0.6	3911	58.0	62.3	0.7	62.4	0.7	8923	54.2	60.9	0.5	61.0	0.5
75+	3689	33.0	52.3	0.8	53.3	0.8	4260	35.8	50.5	0.7	52.2	0.7	7949	34.5	51.4	0.5	52.7	0.5
<b>RECTUM</b>																		
15-44	215	63.0	63.4	2.7	63.4	2.7	207	66.8	67.1	2.7	67.1	2.7	422	64.8	65.2	1.9	65.2	1.9
45-54	687	60.6	61.9	1.5	61.9	1.5	628	66.8	67.6	1.6	67.6	1.6	1315	63.4	64.5	1.1	64.5	1.1
55-64	1727	58.6	61.9	1.0	61.9	1.0	1210	66.1	67.9	1.2	67.9	1.2	2937	61.5	64.2	0.8	64.2	0.8
65-74	2391	51.3	59.3	0.9	59.4	0.9	1632	57.1	61.2	1.0	61.3	1.0	4023	53.5	60.1	0.7	60.2	0.7
75+	1419	29.2	46.3	1.1	47.2	1.2	1402	29.9	42.1	1.0	43.6	1.1	2821	29.6	44.1	0.8	45.4	0.8
<b>COLON RECTUM</b>																		
15-44	593	63.0	63.5	1.6	63.5	1.6	591	64.1	64.4	1.6	64.4	1.6	1184	63.6	63.9	1.1	63.9	1.1
45-54	1856	61.2	62.5	0.9	62.5	0.9	1735	64.8	65.5	1.0	65.5	1.0	3591	62.9	63.9	0.7	63.9	0.7
55-64	4913	60.0	63.4	0.6	63.4	0.6	3843	66.1	67.9	0.7	67.9	0.7	8756	62.5	65.3	0.4	65.3	0.4
65-74	7403	51.5	59.7	0.5	59.7	0.5	5543	57.7	62.0	0.6	62.1	0.6	12946	54.0	60.6	0.4	60.7	0.4
75+	5108	31.8	50.5	0.6	51.5	0.6	5662	34.2	48.2	0.6	49.8	0.6	10770	33.0	49.3	0.4	50.6	0.4
<b>LIVER</b>																		
15-44	61	23.7	23.9	2.9	23.9	2.9	26	35.7	35.8	6.2	35.8	6.2	87	26.3	26.5	2.7	26.5	2.7
45-54	219	22.5	23.0	1.5	23.0	1.5	40	22.5	22.8	3.3	22.8	3.3	259	22.5	23.0	1.3	23.0	1.3
55-64	606	17.9	18.9	0.8	18.9	0.8	137	18.0	18.5	1.5	18.5	1.5	743	17.9	18.8	0.7	18.8	0.7
65-74	769	12.3	14.3	0.6	14.4	0.6	323	14.3	15.4	0.9	15.4	0.9	1092	12.9	14.6	0.5	14.7	0.5
75+	311	5.7	8.4	0.6	8.8	0.6	199	5.2	6.8	0.5	7.4	0.6	510	5.5	7.7	0.4	8.1	0.4
<b>BILIARY TRACT</b>																		
15-44	19	43.2	43.5	7.7	43.5	7.7	14	-	-	-	-	-	33	41.1	41.4	5.6	41.4	5.6
45-54	37	23.3	23.8	3.4	23.9	3.4	40	22.8	23.1	3.4	23.1	3.4	77	23.1	23.5	2.4	23.5	2.4
55-64	87	15.8	16.7	1.7	16.7	1.7	107	17.5	18.0	1.7	18.0	1.7	194	16.7	17.4	1.2	17.4	1.2
65-74	151	13.4	15.5	1.3	15.6	1.3	180	12.9	14.0	1.0	14.0	1.0	331	13.2	14.7	0.8	14.7	0.8
75+	89	5.8	9.1	1.1	9.6	1.1	171	6.3	8.7	0.7	9.4	0.8	260	6.1	8.9	0.6	9.5	0.6

Table 2. Number of initial records, 5-year observed survival (50S), 5-year relative survival (5RS) and standard error (SE) by age, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Age	MALE						FEMALE						MALE & FEMALE					
	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %
<b>PANCREAS</b>																		
15-44	37	19.8	19.9	3.0	19.9	3.0	44	32.6	32.8	4.1	32.8	4.1	81	25.2	25.4	2.5	25.4	2.5
45-54	50	7.8	8.0	1.1	8.0	1.1	57	15.6	15.8	2.0	15.8	2.0	107	10.7	10.9	1.0	10.9	1.0
55-64	114	5.9	6.3	0.6	6.3	0.6	106	8.2	8.4	0.9	8.4	0.9	220	6.8	7.1	0.5	7.1	0.5
65-74	124	4.3	4.9	0.5	4.9	0.5	124	4.8	5.2	0.5	5.2	0.5	248	4.5	5.1	0.3	5.1	0.3
75+	62	1.8	2.8	0.4	2.9	0.4	108	2.2	3.2	0.3	3.3	0.3	170	2.0	3.0	0.3	3.1	0.3
<b>LARYNX</b>																		
15-44	115	69.8	70.4	3.7	70.4	3.7	22	88.4	88.7	6.3	88.8	6.3	137	72.3	72.9	3.3	72.9	3.3
45-54	624	72.4	73.9	1.6	74.0	1.6	77	75.1	76.0	4.4	76.0	4.4	701	72.7	74.2	1.5	74.2	1.5
55-64	1469	68.2	72.1	1.1	72.1	1.1	129	73.7	75.6	3.5	75.6	3.5	1598	68.6	72.4	1.0	72.4	1.0
65-74	1538	60.8	70.3	1.2	70.4	1.2	135	61.1	65.7	3.6	65.7	3.6	1673	60.9	69.9	1.1	70.0	1.1
75+	720	41.1	62.8	1.9	63.3	2.0	85	41.0	57.1	4.9	58.2	5.0	805	41.1	62.2	1.8	62.7	1.8
<b>LUNG</b>																		
15-44	141	23.6	23.8	1.8	23.8	1.8	116	29.9	30.0	2.3	30.0	2.3	257	26.1	26.3	1.4	26.3	1.4
45-54	503	15.5	15.9	0.7	15.9	0.7	285	22.6	22.8	1.2	22.8	1.2	788	17.6	17.9	0.6	17.9	0.6
55-64	1616	15.0	15.9	0.4	15.9	0.4	557	21.1	21.6	0.9	21.6	0.9	2173	16.2	17.0	0.4	17.1	0.4
65-74	2473	11.7	13.6	0.3	13.6	0.3	725	15.3	16.4	0.6	16.5	0.6	3198	12.4	14.1	0.3	14.2	0.3
75+	943	4.6	6.9	0.3	7.2	0.3	423	6.5	8.8	0.5	9.2	0.5	1366	5.1	7.4	0.2	7.8	0.2
<b>BONE</b>																		
15-44	107	64.7	65.0	3.7	65.0	3.7	81	77.9	78.0	4.1	78.0	4.1	188	69.7	70.0	2.8	70.0	2.8
45-54	38	57.8	59.0	6.5	59.0	6.5	38	82.8	83.7	5.6	83.7	5.6	76	68.5	69.6	4.6	69.7	4.6
55-64	35	45.0	47.5	6.3	47.6	6.4	21	52.5	53.9	8.1	53.9	8.1	56	47.7	49.8	5.0	49.9	5.0
65-74	45	42.8	49.3	6.1	49.2	6.1	39	49.8	53.5	6.4	53.5	6.4	84	45.9	51.3	4.4	51.2	4.4
75+	11	-	-	-	-	-	14	-	-	-	-	-	25	12.1	17.6	3.9	18.3	4.1
<b>SKIN MELANOMA</b>																		
15-44	1235	87.9	88.5	0.9	88.5	0.9	1816	94.4	94.7	0.5	94.7	0.5	3051	91.7	92.1	0.5	92.1	0.5
45-54	830	84.8	86.6	1.2	86.6	1.2	904	89.8	90.7	1.0	90.8	1.0	1734	87.3	88.7	0.8	88.7	0.8
55-64	1119	77.9	82.1	1.2	82.1	1.2	978	87.9	90.1	1.0	90.1	1.0	2097	82.3	85.7	0.8	85.7	0.8
65-74	1009	68.0	78.3	1.4	78.4	1.4	960	81.4	87.2	1.3	87.2	1.3	1969	74.0	82.3	1.0	82.5	1.0
75+	513	41.5	66.2	2.4	66.6	2.5	678	51.5	73.3	2.1	75.1	2.2	1191	46.7	70.0	1.6	71.2	1.6
<b>MESOTHELIOMA</b>																		
15-54	32	12.2	12.5	2.4	12.5	2.5	16	18.8	19.0	4.8	19.0	4.8	48	13.9	14.2	2.2	14.2	2.2
55-64	54	8.6	9.1	1.4	9.1	1.4	13	-	-	-	-	-	67	8.1	8.5	1.2	8.5	1.2
65-74	43	5.0	5.8	1.0	5.8	1.0	21	8.8	9.4	2.2	9.5	2.2	64	5.9	6.6	0.9	6.7	0.9
75+	31	3.5	5.4	1.2	5.6	1.2	11	-	-	-	-	-	42	3.4	5.0	0.9	5.2	0.9
<b>KAPOSI SARCOMA</b>																		
15-44	114	73.8	74.3	3.5	74.3	3.5	16	67.5	67.7	10.2	67.7	10.2	130	73.1	73.5	3.3	73.5	3.3
45-54	62	81.3	82.8	4.6	82.8	4.6	10	-	-	-	-	-	72	79.4	80.9	4.4	80.9	4.4
55-64	106	83.3	87.7	3.5	87.7	3.5	22	86.3	88.6	7.5	88.6	7.5	128	83.7	87.8	3.2	87.8	3.2
65-74	147	76.1	88.6	3.7	88.5	3.7	71	91.7	98.8	3.5	98.9	3.5	218	80.6	91.6	2.8	91.7	2.8
75+	138	48.7	82.0	5.4	82.0	5.4	125	60.6	92.4	5.5	91.6	5.5	263	53.8	86.5	3.9	86.4	3.9
<b>SOFT TISSUE</b>																		
15-44	219	72.8	73.2	2.6	73.2	2.6	203	80.0	80.2	2.5	80.2	2.5	422	76.1	76.5	1.8	76.5	1.8
45-54	138	69.3	70.7	3.4	70.7	3.4	114	74.3	75.1	3.6	75.1	3.6	252	71.5	72.6	2.5	72.7	2.5
55-64	158	57.9	61.1	3.2	61.1	3.2	141	63.1	64.8	3.4	64.7	3.4	299	60.2	62.7	2.3	62.8	2.3
65-74	173	48.3	55.7	3.2	55.9	3.2	129	47.4	50.9	3.4	50.9	3.4	302	47.9	53.6	2.3	53.7	2.3
75+	106	29.1	46.5	4.1	48.2	4.2	106	31.7	43.4	3.6	45.7	3.8	212	30.4	44.9	2.7	46.8	2.8
<b>BREAST</b>																		
15-44							8056	88.9	89.2	0.3	89.2	0.3						
45-54							13786	90.1	91.1	0.2	91.1	0.2						
55-64							15987	87.3	89.6	0.3	89.6	0.3						
65-74							14712	81.0	86.7	0.3	86.8	0.3						
75+							10450	54.7	76.4	0.5	77.2	0.5						
<b>CERVIX UTERI</b>																		
15-44							957	83.1	83.4	1.1	83.4	1.1						
45-54							599	73.7	74.5	1.6	74.5	1.6						
55-64							553	68.6	70.3	1.7	70.3	1.7						
65-74							398	54.8	58.8	2.0	58.9	2.0						
75+							258	26.7	36.2	2.2	37.7	2.2						

**Table 2.** Number of initial records, 5-year observed survival (50S), 5-year relative survival (5RS) and standard error (SE) by age, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Age	MALE						FEMALE						MALE & FEMALE					
	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %
<b>CORPUS UTERI</b>																		
15-44							398	89.4	89.8	1.5	89.8	1.5						
45-54							1469	87.0	88.1	0.8	88.1	0.8						
55-64							2818	83.8	85.9	0.7	86.0	0.7						
65-74							2381	71.3	76.4	0.9	76.4	0.9						
75+							1391	44.4	59.3	1.3	61.1	1.3						
<b>OVARY</b>																		
15-44							648	76.6	76.9	1.5	76.9	1.5						
45-54							786	57.1	57.8	1.4	57.8	1.4						
55-64							907	46.8	48.0	1.2	48.0	1.2						
65-74							732	31.1	33.3	1.1	33.3	1.1						
75+							356	12.6	17.1	0.9	18.0	1.0						
<b>PROSTATE</b>																		
15-54	1361	88.6	90.7	0.8	90.7	0.8												
55-64	10117	88.3	93.5	0.3	93.5	0.3												
65-74	20549	80.2	92.9	0.3	93.0	0.3												
75-84	11008	58.0	83.8	0.6	84.2	0.6												
85+	929	19.1	51.2	1.8	52.8	1.8												
<b>TESTIS</b>																		
15-44	2004	96.1	96.6	0.4	96.6	0.4												
45-54	246	92.1	93.7	1.7	93.7	1.7												
55-64	90	81.8	85.9	3.9	86.0	3.9												
65-74	51	75.7	86.0	6.2	86.2	6.2												
75+	23	34.9	60.6	11.1	60.8	11.1												
<b>KIDNEY</b>																		
15-44	449	85.6	86.2	1.5	86.2	1.5	250	85.6	85.9	2.1	85.9	2.1	699	85.6	86.1	1.2	86.1	1.2
45-54	864	74.5	76.1	1.3	76.1	1.3	423	80.3	81.3	1.8	81.3	1.8	1287	76.3	77.7	1.1	77.7	1.1
55-64	1683	70.8	74.7	1.0	74.7	1.0	752	76.3	78.4	1.4	78.4	1.4	2435	72.4	75.8	0.8	75.8	0.8
65-74	1976	59.5	68.7	1.0	68.8	1.0	1090	66.3	71.1	1.3	71.1	1.3	3066	61.8	69.5	0.8	69.6	0.8
75+	801	32.1	49.2	1.6	50.6	1.6	771	38.6	52.0	1.5	53.9	1.6	1572	35.1	50.5	1.1	52.2	1.1
<b>URINARY TRACT</b>																		
15-44	40	83.4	84.0	5.8	84.0	5.8	15	72.4	72.6	9.6	72.6	9.6	55	79.9	80.4	5.0	80.4	5.0
45-54	76	70.7	72.2	4.5	72.3	4.5	28	63.2	63.9	7.7	64.0	7.7	104	68.7	70.0	3.9	70.0	3.9
55-64	222	67.1	71.1	2.8	71.2	2.8	63	57.0	58.6	4.9	58.6	4.9	285	64.6	68.0	2.4	68.0	2.4
65-74	386	53.1	61.7	2.2	61.8	2.2	147	55.0	59.2	3.3	59.3	3.3	533	53.7	61.0	1.9	61.0	1.9
75+	241	29.5	45.7	2.7	47.6	2.8	137	29.2	42.5	3.2	43.0	3.3	378	29.4	44.5	2.1	45.7	2.1
<b>URINARY BLADDER</b>																		
15-44	684	94.6	95.3	0.8	95.3	0.8	213	92.6	92.9	1.7	92.9	1.7	897	94.2	94.8	0.8	94.8	0.8
45-54	1816	86.8	88.7	0.8	88.7	0.8	431	90.4	91.5	1.4	91.5	1.4	2247	87.4	89.2	0.7	89.2	0.7
55-64	4923	80.6	85.2	0.5	85.2	0.5	963	82.2	84.4	1.2	84.4	1.2	5886	80.8	85.1	0.5	85.1	0.5
65-74	7769	67.3	78.1	0.5	78.2	0.5	1612	72.5	78.0	1.1	78.1	1.1	9381	68.1	78.1	0.5	78.2	0.5
75+	5279	41.5	65.4	0.8	66.6	0.8	1564	40.8	57.9	1.2	60.3	1.2	6843	41.3	63.6	0.6	65.0	0.7
<b>CHOROID MELANOMA</b>																		
15-44	11	-	-	-	-	-	8	-	-	-	-	-	19	90.5	90.9	6.4	90.9	6.4
45-54	10	-	-	-	-	-	9	-	-	-	-	-	19	79.5	80.9	9.4	80.9	9.4
55-64	20	70.9	74.7	9.8	74.7	9.8	16	100	102.7	0	102.7	0	36	82.3	85.8	6.3	85.9	6.4
65-74	28	71.0	82.1	8.5	81.9	8.5	19	82.6	88.4	8.5	88.2	8.4	47	75.3	84.4	6.2	84.4	6.2
75+	17	42.0	66.5	14.6	67.3	14.7	22	49.8	73.3	11.4	77.4	12.1	39	46.5	70.6	9.0	73.3	9.4
<b>BRAIN AND CENTRAL NERVOUS SYSTEM</b>																		
15-44	359	48.1	48.3	1.9	48.4	1.9	290	56.6	56.8	2.3	56.8	2.3	649	51.6	51.8	1.5	51.8	1.5
45-54	127	22.2	22.6	1.8	22.7	1.8	121	30.2	30.5	2.4	30.5	2.4	248	25.5	25.9	1.5	25.9	1.5
55-64	101	9.0	9.5	1.0	9.5	1.0	118	15.8	16.2	1.4	16.3	1.4	219	11.9	12.4	0.8	12.4	0.8
65-74	75	5.3	6.1	0.7	6.1	0.7	71	6.3	6.7	0.8	6.8	0.8	146	5.7	6.4	0.6	6.4	0.6
75+	30	3.0	4.5	0.9	4.7	0.9	61	4.6	6.1	0.8	6.3	0.9	91	3.9	5.5	0.6	5.7	0.6
<b>THYROID</b>																		
15-44	818	98.6	99.1	0.4	99.1	0.4	2991	99.4	99.7	0.1	99.7	0.1	3809	99.2	99.6	0.1	99.6	0.1
45-54	435	93.9	95.7	1.1	95.7	1.1	1706	98.0	99.1	0.3	99.1	0.3	2141	97.1	98.4	0.4	98.4	0.4
55-64	496	85.3	89.8	1.6	89.8	1.6	1589	94.4	96.8	0.6	96.8	0.6	2085	92.1	95.0	0.6	95.1	0.6
65-74	347	68.9	79.3	2.4	79.4	2.4	1019	85.6	91.4	1.1	91.4	1.1	1366	80.7	87.9	1.1	88.1	1.1
75+	107	42.7	62.3	5.0	64.7	5.2	299	43.7	57.3	2.6	60.1	2.7	406	43.4	58.5	2.3	61.2	2.4

**Table 2.** Number of initial records, 5-year observed survival (50S), 5-year relative survival (5RS) and standard error (SE) by age, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CONTINUED OVERLEAF&gt;&gt;



&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Age	MALE						FEMALE						MALE & FEMALE					
	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %	No.	50S%	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	5SE <sup>[b]</sup> %
<b>HODGKIN LYMPHOMA</b>																		
15-44	859	91.2	91.7	0.9	91.7	0.9	789	94.2	94.4	0.8	94.4	0.8	1648	92.6	93.0	0.6	93.0	0.6
45-54	168	84.8	86.4	2.7	86.4	2.7	113	85.8	86.7	3.1	86.7	3.1	281	85.2	86.6	2.0	86.6	2.0
55-64	134	75.1	79.2	3.5	79.2	3.5	111	82.6	84.7	3.5	84.7	3.5	245	78.3	81.6	2.5	81.6	2.5
65-74	112	51.4	59.1	4.0	59.3	4.0	83	59.0	63.3	4.7	63.4	4.7	195	54.3	60.7	3.1	60.9	3.1
75+	25	21.3	30.7	6.1	32.5	6.4	54	34.4	45.1	5.2	47.1	5.5	79	29.1	39.5	4.0	41.6	4.2
<b>NON HODGKIN LYMPHOMA</b>																		
15-44	1047	74.4	74.9	1.2	74.9	1.2	719	79.9	80.2	1.3	80.2	1.3	1766	76.6	77.0	0.9	77.0	0.9
45-54	890	73.7	75.2	1.3	75.2	1.3	694	78.2	79.1	1.4	79.1	1.4	1584	75.6	76.9	1.0	76.9	1.0
55-64	1292	64.0	67.5	1.2	67.5	1.2	1184	71.7	73.6	1.2	73.6	1.2	2476	67.5	70.3	0.8	70.3	0.8
65-74	1581	50.8	58.7	1.1	58.8	1.1	1499	56.6	60.8	1.1	60.9	1.1	3080	53.5	59.7	0.8	59.8	0.8
75+	775	26.8	41.3	1.4	42.8	1.4	1015	28.1	38.1	1.1	39.6	1.1	1790	27.5	39.5	0.9	40.9	0.9
<b>MYELOMA</b>																		
15-44	82	79.0	79.6	4.1	79.6	4.1	61	86.9	87.2	4.1	87.2	4.1	143	82.2	82.7	3.0	82.7	3.0
45-54	200	59.9	61.2	2.9	61.2	2.9	205	66.8	67.6	2.9	67.6	2.9	405	63.3	64.3	2.1	64.3	2.1
55-64	462	55.7	58.7	1.9	58.8	1.9	374	56.8	58.3	2.1	58.3	2.1	836	56.1	58.5	1.4	58.6	1.4
65-74	518	35.0	40.4	1.6	40.5	1.6	479	37.2	40.0	1.6	40.0	1.6	997	36.0	40.2	1.1	40.3	1.1
75+	291	17.2	27.5	1.7	28.3	1.8	385	18.6	25.7	1.4	26.7	1.4	676	17.9	26.4	1.1	27.4	1.1
<b>ACUTE LYMPHATIC LEUKAEMIA</b>																		
15-44	59	36.8	37.0	3.9	37.0	3.9	50	42.0	42.1	4.8	42.1	4.8	109	38.9	39.1	3.0	39.1	3.0
45-54	5	-	-	-	-	-	15	38.5	38.9	7.9	38.9	7.9	20	27.2	27.6	5.2	27.6	5.2
55-64	9	-	-	-	-	-	11	-	-	-	-	-	20	19.2	19.9	4.1	20.0	4.1
65-74	6	-	-	-	-	-	11	-	-	-	-	-	17	14.8	16.3	3.7	16.6	3.7
75+	6	-	-	-	-	-	10	-	-	-	-	-	16	7.9	11.0	3.2	12.0	3.5
<b>CHRONIC LYMPHATIC LEUKAEMIA</b>																		
15-44	44	87.2	87.8	4.9	87.8	4.9	41	94.9	95.3	3.5	95.3	3.5	85	90.8	91.3	3.1	91.3	3.1
45-54	200	87.1	89.0	2.4	89.0	2.4	98	87.6	88.6	3.3	88.6	3.3	298	87.3	88.8	1.9	88.8	1.9
55-64	441	76.9	81.3	1.9	81.3	1.9	241	86.2	88.6	2.2	88.6	2.2	682	80.0	83.7	1.5	83.8	1.5
65-74	589	60.8	70.5	1.9	70.6	1.9	433	69.9	75.3	2.1	75.4	2.1	1022	64.4	72.4	1.4	72.5	1.4
75+	385	32.2	52.8	2.5	54.5	2.6	396	35.6	52.0	2.3	53.9	2.4	781	33.9	52.4	1.7	54.2	1.8
<b>ACUTE MYELOID LEUKAEMIA</b>																		
15-44	139	55.0	55.3	3.2	55.3	3.2	138	55.4	55.6	3.2	55.6	3.2	277	55.2	55.5	2.2	55.5	2.2
45-54	71	38.1	38.9	3.7	38.9	3.7	61	33.7	34.1	3.7	34.1	3.7	132	36.0	36.5	2.6	36.5	2.6
55-64	61	14.0	14.8	2.0	14.8	2.0	61	20.9	21.4	2.5	21.5	2.5	122	17.0	17.7	1.6	17.7	1.6
65-74	28	4.1	4.7	1.0	4.8	1.0	51	10.0	10.7	1.5	10.7	1.5	79	6.7	7.4	0.9	7.5	0.9
75+	18	1.8	3.0	0.9	3.0	0.8	21	2.6	3.5	0.8	3.7	0.8	39	2.2	3.3	0.6	3.4	0.6
<b>CHRONIC MYELOID LEUKAEMIA</b>																		
15-44	132	93.1	93.6	2.1	93.6	2.1	80	89.8	90.0	3.2	90.0	3.2	212	91.8	92.2	1.8	92.2	1.8
45-54	45	66.1	67.4	6.2	67.4	6.2	75	82.1	83.0	4.3	83.0	4.3	120	75.3	76.4	3.6	76.4	3.6
55-64	101	56.8	59.9	4.1	60.0	4.1	76	64.1	65.8	4.6	65.8	4.6	177	59.8	62.4	3.1	62.4	3.1
65-74	103	31.6	36.8	3.2	37.0	3.2	93	44.3	47.4	4.0	47.6	4.0	196	36.5	41.0	2.5	41.3	2.5
75+	79	15.0	23.7	2.9	24.6	3.0	84	19.6	28.5	3.2	29.5	3.3	163	17.2	26.0	2.2	27.0	2.2
<b>ALL LEUKAEMIAS</b>																		
15-44	441	63.6	64.0	1.9	64.0	1.9	341	62.4	62.5	2.1	62.5	2.1	782	63.1	63.3	1.4	63.3	1.4
45-54	403	64.2	65.5	2.0	65.5	2.0	279	60.1	60.7	2.4	60.7	2.4	682	62.4	63.5	1.5	63.5	1.5
55-64	729	53.2	56.2	1.5	56.3	1.5	430	52.7	54.1	1.8	54.1	1.8	1159	53.0	55.4	1.1	55.4	1.2
65-74	811	36.1	41.8	1.2	41.9	1.2	630	40.7	43.7	1.4	43.8	1.4	1441	38.0	42.6	0.9	42.7	0.9
75+	536	17.3	28.0	1.3	28.9	1.3	566	19.1	27.5	1.1	28.4	1.2	1102	18.2	27.7	0.8	28.6	0.9
<b>ALL BUT SKIN, NON MELANOMA</b>																		
15-44	10482	74.5	75.0	0.4	75.0	0.4	19644	84.4	84.7	0.2	84.7	0.2	30126	80.7	81.1	0.2	81.1	0.2
45-54	12789	56.5	57.8	0.3	57.8	0.3	25148	78.1	79.0	0.2	79.0	0.2	37937	69.3	70.3	0.2	70.3	0.2
55-64	33870	53.5	56.5	0.2	56.6	0.2	33873	69.4	71.2	0.2	71.2	0.2	67743	60.5	63.0	0.2	63.1	0.2
65-74	51902	46.5	53.8	0.2	53.9	0.2	35973	55.0	59.0	0.2	59.1	0.2	87875	49.6	55.8	0.1	55.9	0.1
75+	30424	27.1	42.3	0.2	43.5	0.2	27799	29.0	40.6	0.2	42.1	0.2	58223	28.0	41.5	0.2	42.8	0.2
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>																		
15-44	9798	73.4	73.8	0.4	73.9	0.4	19431	84.3	84.7	0.2	84.7	0.2	29229	80.3	80.7	0.2	80.7	0.2
45-54	10973	53.4	54.5	0.4	54.6	0.4	24717	77.9	78.8	0.2	78.8	0.2	35690	68.4	69.4	0.2	69.4	0.2
55-64	28947	50.5	53.4	0.2	53.4	0.2	32910	69.1	70.9	0.2	70.9	0.2	61857	59.0	61.5	0.2	61.6	0.2
65-74	44133	44.0	51.0	0.2	51.1	0.2	34361	54.4	58.4	0.2	58.5	0.2	78494	48.1	53.9	0.1	54.1	0.1
75+	25145	25.3	39.4	0.2	40.5	0.2	26235	28.5	39.8	0.2	41.3	0.2	51380	26.8	39.6	0.2	40.9	0.2

**Table 2.** Number of initial records, 5-year observed survival (5OS), 5-year relative survival (5RS) and standard error (SE) by age, gender and site. Pool of 31 cancer registries, 2000-2004. [a]=Ederer II method; [b]=Hakulinen method

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>HEAD AND NECK</b>												
North-West	56.5	1.0	56.7	1.0	55.1	1.7	55.3	1.7	55.6	0.9	55.8	0.9
North-East	53.7	0.8	53.8	0.8	56.7	1.4	57.2	1.4	54.0	0.7	54.2	0.7
Centre	57.4	1.5	57.6	1.5	57.5	2.7	58.0	2.7	57.5	1.3	57.7	1.3
South	55.0	1.6	55.5	1.6	57.6	3.1	58.3	3.2	55.5	1.4	56.0	1.4
Pool	55.1	0.5	55.3	0.6	56.4	0.9	56.8	1.0	55.1	0.5	55.3	0.5
<b>SALIVARY GLANDS</b>												
North-West	51.7	4.1	52.3	4.2	65.8	4.5	66.2	4.5	58.0	3.1	58.7	3.1
North-East	54.7	3.6	55.0	3.6	64.5	4.0	65.3	4.1	58.6	2.7	59.1	2.8
Centre	65.7	5.3	66.4	5.5	66.1	5.5	67.0	5.7	65.8	3.8	66.5	3.9
South	50.2	5.6	49.6	5.4	57.4	6.9	57.7	6.9	52.7	4.3	52.8	4.3
Pool	54.9	2.2	55.3	2.3	64.4	2.5	65.1	2.5	58.6	1.7	59.2	1.7
<b>OESOPHAGUS</b>												
North-West	10.6	1.2	10.7	1.2	14.5	2.4	14.6	2.4	11.5	1.0	11.7	1.0
North-East	11.8	0.9	11.9	0.9	15.9	2.2	16.1	2.2	12.6	0.8	12.7	0.8
Centre	10.3	2.2	10.2	2.1	-	-	-	-	10.8	1.9	10.8	1.9
South	7.7	1.8	7.7	1.8	4.6	3.2	4.6	3.2	6.7	1.5	6.7	1.5
Pool	11.1	0.6	11.1	0.6	14.0	1.3	14.2	1.4	11.6	0.6	11.8	0.6
<b>STOMACH</b>												
North-West	31.6	0.9	31.9	0.9	34.2	1.1	34.5	1.1	32.7	0.7	33.0	0.7
North-East	30.4	0.7	30.7	0.7	36.7	0.9	37.3	0.9	32.7	0.5	33.2	0.5
Centre	30.2	1.0	30.5	1.1	37.0	1.3	37.5	1.4	32.7	0.8	33.2	0.8
South	27.0	1.3	27.3	1.3	32.9	1.7	33.3	1.7	29.4	1.0	29.8	1.1
Pool	30.3	0.4	30.6	0.5	35.7	0.6	36.2	0.6	32.4	0.3	32.8	0.4
<b>SMALL INTESTINE</b>												
North-West	46.4	3.6	46.8	3.6	56.3	3.9	56.5	3.9	50.1	2.6	50.5	2.7
North-East	50.4	2.9	50.4	2.9	52.7	2.9	53.5	3.0	51.6	2.0	52.0	2.1
Centre	54.8	5.5	55.4	5.6	49.7	6.1	49.1	5.9	52.8	4.1	52.9	4.1
South	43.5	5.8	43.6	5.9	36.9	5.3	37.0	5.4	40.5	4.0	40.6	4.0
Pool	48.6	2.0	48.8	2.0	51.3	2.0	51.8	2.1	49.7	1.4	50.0	1.4
<b>COLON</b>												
North-West	57.9	0.7	58.2	0.7	60.4	0.7	60.9	0.7	59.1	0.5	59.5	0.5
North-East	60.3	0.6	60.6	0.6	61.2	0.6	61.8	0.6	60.6	0.4	61.1	0.4
Centre	59.9	1.0	60.2	1.0	62.1	1.0	62.5	1.0	60.9	0.7	61.2	0.7
South	57.9	1.2	58.2	1.2	56.1	1.2	56.6	1.2	56.8	0.8	57.2	0.8
Pool	59.3	0.4	59.6	0.4	60.5	0.4	61.0	0.4	59.8	0.3	60.2	0.3
<b>RECTUM</b>												
North-West	55.7	1.0	56.0	1.0	58.9	1.0	59.3	1.0	56.8	0.7	57.2	0.7
North-East	59.3	0.8	59.6	0.9	58.0	0.9	58.5	0.9	58.7	0.6	59.1	0.6
Centre	55.6	1.3	55.8	1.3	60.1	1.4	60.7	1.4	57.5	0.9	57.9	1.0
South	52.6	1.5	52.9	1.5	55.7	1.6	56.0	1.6	53.7	1.1	54.1	1.1
Pool	56.7	0.5	57.0	0.5	58.4	0.6	58.9	0.6	57.3	0.4	57.7	0.4
<b>COLON RECTUM</b>												
North-West	57.3	0.6	57.6	0.6	60.1	0.6	60.5	0.6	58.5	0.4	58.9	0.4
North-East	60.0	0.5	60.3	0.5	60.4	0.5	60.9	0.5	60.1	0.3	60.5	0.3
Centre	58.4	0.8	58.6	0.8	61.5	0.8	62.0	0.8	59.7	0.6	60.1	0.6
South	55.9	0.9	56.2	0.9	56.0	0.9	56.5	0.9	55.8	0.7	56.1	0.7
Pool	58.5	0.3	58.8	0.3	59.9	0.3	60.4	0.3	59.0	0.2	59.4	0.2
<b>LIVER</b>												
North-West	17.1	0.7	17.3	0.7	17.6	1.4	17.8	1.4	17.3	0.6	17.4	0.6
North-East	14.6	0.6	14.7	0.6	15.3	1.3	15.5	1.3	14.7	0.5	14.8	0.5
Centre	13.8	1.2	14.0	1.2	17.4	2.4	17.6	2.4	14.7	1.1	14.9	1.1
South	15.0	1.0	15.1	1.0	13.6	1.5	13.7	1.5	14.2	0.8	14.2	0.8
Pool	15.4	0.4	15.5	0.4	16.0	0.8	16.1	0.8	15.4	0.3	15.6	0.3
<b>BILIARY TRACT</b>												
North-West	16.8	1.6	17.0	1.6	18.2	1.8	18.4	1.8	17.5	1.2	17.7	1.2
North-East	17.5	1.5	17.6	1.6	16.4	1.5	16.7	1.5	16.9	1.1	17.2	1.1
Centre	17.5	2.5	17.7	2.5	15.0	2.1	15.3	2.1	16.3	1.6	16.5	1.6
South	14.6	2.0	14.8	2.0	13.6	1.7	13.7	1.7	14.1	1.3	14.1	1.3
Pool	16.9	0.9	17.1	0.9	16.2	0.9	16.5	0.9	16.5	0.6	16.7	0.6

**Table 3.** Five-year age-standardized relative survival (5RS) and standard error (SE) by macroarea, gender and site. Pool of 31 cancer registries, 2000-2004. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CONTINUA&gt;&gt;

CANCER SITE	MALE				FEMALE				MALE & FEMALE			
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>PANCREAS</b>												
North-West	6.8	0.7	6.9	0.7	9.2	0.9	9.2	0.9	7.8	0.5	7.8	0.5
North-East	5.5	0.5	5.5	0.5	8.4	0.7	8.4	0.7	6.6	0.4	6.6	0.4
Centre	5.6	0.9	5.7	0.9	9.6	1.3	9.6	1.4	7.2	0.8	7.2	0.8
South	6.3	0.9	6.3	0.9	7.7	1.2	7.8	1.2	6.8	0.7	6.8	0.7
Pool	6.0	0.3	6.1	0.3	8.5	0.5	8.6	0.5	7.1	0.3	7.1	0.3
<b>LARYNX</b>												
North-West	70.4	1.4	70.6	1.4	62.5	3.7	63.1	3.8	69.6	1.3	69.8	1.3
North-East	68.3	1.2	68.3	1.2	73.1	2.9	73.3	2.9	68.7	1.1	68.8	1.1
Centre	69.9	1.9	70.1	1.9	63.0	6.0	62.9	6.0	69.4	1.8	69.6	1.8
South	66.8	2.1	67.4	2.1	70.3	6.8	70.9	6.9	67.2	2.0	67.8	2.0
Pool	69.0	0.8	69.2	0.8	68.3	2.1	68.7	2.1	69.0	0.7	69.1	0.7
<b>LUNG</b>												
North-West	13.0	0.4	13.1	0.4	16.9	0.6	17.0	0.6	14.0	0.3	14.2	0.3
North-East	13.6	0.3	13.7	0.3	17.3	0.6	17.5	0.6	14.5	0.3	14.6	0.3
Centre	14.2	0.6	14.3	0.6	18.6	1.0	18.7	1.0	15.4	0.5	15.5	0.5
South	11.5	0.5	11.6	0.5	15.1	1.1	15.2	1.2	12.1	0.4	12.3	0.4
Pool	13.2	0.2	13.3	0.2	17.1	0.4	17.3	0.4	14.1	0.2	14.3	0.2
<b>BONE</b>												
North-West	42.0	4.7	42.3	4.9	55.9	5.2	56.0	5.2	48.8	3.5	49.1	3.6
North-East	50.4	4.1	50.5	4.2	62.6	4.4	62.5	4.4	55.1	3.1	55.1	3.1
Centre	55.1	6.3	55.4	6.3	63.2	6.2	63.4	6.3	59.4	4.4	59.7	4.5
South	55.2	5.2	55.3	5.3	60.1	5.9	59.7	5.8	56.6	4.1	56.4	4.1
Pool	50.2	2.5	50.3	2.5	60.8	2.7	60.9	2.7	54.6	1.8	54.7	1.9
<b>SKIN MELANOMA</b>												
North-West	83.6	1.0	83.8	1.0	90.2	0.8	90.5	0.8	86.7	0.7	87.0	0.7
North-East	82.1	0.9	82.1	0.9	88.9	0.7	89.1	0.7	85.7	0.6	85.8	0.6
Centre	81.7	1.5	81.9	1.5	87.6	1.2	88.0	1.3	84.6	1.0	85.0	1.0
South	72.5	2.2	72.8	2.2	82.3	2.0	82.5	2.0	77.2	1.5	77.5	1.5
Pool	81.6	0.6	81.7	0.6	88.6	0.5	88.8	0.5	85.1	0.4	85.3	0.4
<b>MESOTHELIOMA</b>												
North-West	7.0	1.0	7.1	1.1	6.7	1.6	6.7	1.6	6.8	0.9	6.9	0.9
North-East	7.1	1.1	7.2	1.1	10.4	2.4	10.5	2.4	7.8	1.0	7.9	1.0
Centre	7.8	2.5	7.8	2.6	16.1	6.0	16.1	6.0	11.1	2.8	11.2	2.8
South	14.8	3.2	14.6	3.2	10.1	3.7	10.1	3.7	13.5	2.5	13.3	2.5
Pool	7.7	0.7	7.8	0.7	9.1	1.3	9.1	1.3	8.0	0.6	8.1	0.6
<b>KAPOSI SARCOMA</b>												
North-West	85.1	3.2	84.6	3.2	80.5	5.5	79.6	5.5	84.4	2.6	83.7	2.6
North-East	85.8	3.7	86.3	3.7	98.6	3.9	99.5	3.9	90.4	2.8	91.2	2.9
Centre	87.7	7.8	88.3	7.9	89.6	8.8	88.0	8.6	89.1	6.6	89.0	6.6
South	82.7	5.6	82.6	5.6	95.9	3.7	96.2	3.7	85.6	4.0	85.9	4.1
Pool	84.8	2.2	84.8	2.2	88.9	3.1	88.7	3.1	86.7	1.7	86.7	1.7
<b>SOFT TISSUE</b>												
North-West	63.8	2.5	64.2	2.5	66.1	2.5	66.5	2.5	64.6	1.8	65.0	1.8
North-East	63.2	2.3	63.5	2.3	64.9	2.3	65.1	2.3	64.0	1.6	64.3	1.7
Centre	61.1	3.9	61.1	3.8	61.1	3.8	61.5	3.8	61.2	2.7	61.4	2.7
South	62.4	3.7	62.7	3.7	69.6	4.3	70.2	4.4	65.1	2.8	65.5	2.9
Pool	63.0	1.4	63.3	1.4	65.1	1.5	65.4	1.5	63.9	1.0	64.2	1.0
<b>BREAST</b>												
North-West					86.5	0.3	86.8	0.3				
North-East					85.1	0.3	85.4	0.3				
Centre					85.8	0.5	86.2	0.5				
South					81.4	0.6	81.6	0.6				
Pool					85.1	0.2	85.3	0.2				
<b>CERVIX UTERI</b>												
North-West					67.3	1.3	67.6	1.3				
North-East					67.5	1.2	67.6	1.2				
Centre					69.8	1.9	70.1	1.9				
South					65.4	2.0	65.7	2.0				
Pool					67.6	0.7	67.9	0.8				

Table 3. Five-year age-standardized relative survival (SRS) and standard error (SE) by macroarea, gender and site.

CONTINUED OVERLEAF&gt;&gt;

Pool of 31 cancer registries, 2000-2004. [a] Ederer II method; [b] Hakulinen method

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>CORPUS UTERI</b>												
North-West					77.5	0.9	78.2	0.9				
North-East					76.2	0.8	76.7	0.8				
Centre					75.7	1.3	76.2	1.3				
South					71.4	1.4	71.9	1.4				
Pool					76.0	0.5	76.5	0.5				
<b>OVARY</b>												
North-West					38.2	1.0	38.6	1.0				
North-East					37.3	0.9	37.6	0.9				
Centre					41.2	1.5	41.3	1.5				
South					35.4	1.5	35.6	1.5				
Pool					38.0	0.5	38.3	0.6				
<b>PROSTATE</b>												
North-West	90.6	0.4	90.8	0.4								
North-East	88.6	0.4	88.8	0.4								
Centre	85.4	0.8	85.6	0.8								
South	78.2	1.1	78.3	1.1								
Pool	88.0	0.3	88.2	0.3								
<b>TESTIS</b>												
North-West	89.5	2.3	89.4	2.3								
North-East	89.0	2.0	89.6	2.1								
Centre	96.4	4.1	95.8	3.8								
South	90.3	6.0	91.4	6.9								
Pool	90.6	1.4	90.6	1.4								
<b>KIDNEY</b>												
North-West	65.8	1.1	66.2	1.2	67.8	1.3	68.3	1.4	66.5	0.9	66.9	0.9
North-East	67.4	0.9	67.9	0.9	71.9	1.0	72.5	1.1	69.2	0.7	69.8	0.7
Centre	68.8	1.5	69.2	1.5	69.8	1.8	70.3	1.8	68.9	1.1	69.4	1.2
South	60.3	2.1	60.9	2.2	62.8	2.5	63.3	2.5	61.3	1.6	61.8	1.6
Pool	66.5	0.6	67.0	0.6	69.5	0.7	70.0	0.7	67.6	0.5	68.1	0.5
<b>URINARY TRACT</b>												
North-West	62.1	2.4	62.6	2.4	56.9	3.6	56.8	3.6	60.5	2.0	60.7	2.0
North-East	62.4	2.0	63.1	2.0	52.3	3.2	52.6	3.2	59.7	1.7	60.1	1.7
Centre	64.2	4.0	64.5	4.0	59.0	5.8	59.4	5.9	62.6	3.3	63.0	3.3
South	57.9	4.8	58.2	4.8	60.9	8.3	60.9	8.3	59.1	4.0	59.3	4.1
Pool	62.1	1.4	62.6	1.4	55.7	2.1	55.9	2.1	60.3	1.1	60.6	1.2
<b>URINARY BLADDER</b>												
North-West	78.9	0.6	79.4	0.6	76.1	1.0	77.0	1.0	78.3	0.5	78.8	0.5
North-East	78.9	0.5	79.4	0.5	76.2	0.9	76.8	0.9	78.2	0.4	78.7	0.4
Centre	77.9	0.8	78.3	0.8	77.2	1.4	77.7	1.5	77.8	0.7	78.2	0.7
South	77.0	0.8	77.2	0.8	75.8	1.7	76.2	1.7	76.8	0.7	77.0	0.7
Pool	78.5	0.3	78.9	0.3	76.3	0.6	77.0	0.6	78.0	0.3	78.4	0.3
<b>CHOROID MELANOMA</b>												
North-West	93.5	8.5	93.5	8.5	85.6	10.8	85.0	10.7	90.1	6.7	89.8	6.6
North-East	73.9	9.5	73.3	9.3	81.5	7.3	82.7	7.5	78.5	5.8	79.3	5.9
Centre	88.0	10.0	87.6	9.9	76.5	10.0	80.3	10.9	83.4	7.0	84.8	7.3
South	51.2	13.9	52.4	14.7	98.7	10.7	100.5	11.4	69.8	10.8	71.2	11.2
Pool	76.7	5.6	76.9	5.7	86.1	4.5	87.3	4.7	80.8	3.7	81.5	3.8
<b>BRAIN AND CENTRAL NERVOUS SYSTEM</b>												
North-West	22.2	1.3	22.2	1.3	27.6	1.7	27.7	1.7	24.4	1.0	24.4	1.0
North-East	19.9	1.1	19.9	1.1	23.6	1.3	23.7	1.3	21.5	0.8	21.5	0.8
Centre	23.7	1.8	23.8	1.8	31.7	2.1	31.7	2.1	27.0	1.4	27.1	1.4
South	20.4	1.6	20.4	1.6	28.4	2.0	28.3	2.0	24.0	1.3	24.0	1.3
Pool	21.2	0.7	21.3	0.7	26.7	0.8	26.7	0.8	23.5	0.5	23.6	0.5
<b>THYROID</b>												
North-West	89.2	1.8	89.6	1.8	91.5	0.9	91.9	0.9	90.9	0.8	91.3	0.8
North-East	89.1	1.4	89.5	1.4	92.8	0.6	93.3	0.7	91.7	0.6	92.2	0.6
Centre	87.9	2.4	88.1	2.4	89.1	1.2	89.3	1.2	88.8	1.1	89.0	1.1
South	77.8	2.5	78.1	2.6	88.6	1.3	89.0	1.3	85.9	1.2	86.4	1.2
Pool	87.5	0.9	87.8	1.0	91.4	0.5	91.8	0.5	90.3	0.4	90.8	0.4

**Table 3.** Five-year age-standardized relative survival (5RS) and standard error (SE) by macroarea, gender and site. Pool of 31 cancer registries, 2000-2004. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>HODGKIN LYMPHOMA</b>												
North-West	78.3	2.0	78.5	2.0	83.9	1.8	84.1	1.8	81.1	1.3	81.2	1.4
North-East	82.8	1.6	82.9	1.6	85.0	1.4	85.1	1.5	84.0	1.1	84.2	1.1
Centre	79.7	2.5	80.1	2.6	81.2	2.7	81.6	2.8	80.3	1.8	80.7	1.9
South	80.7	2.6	80.9	2.6	88.0	2.9	88.3	2.9	84.6	2.0	84.9	2.0
Pool	80.6	1.0	80.8	1.0	84.7	1.0	84.9	1.0	82.6	0.7	82.9	0.7
<b>NON HODGKIN LYMPHOMA</b>												
North-West	58.1	1.1	58.6	1.1	60.3	1.0	60.9	1.0	59.1	0.7	59.7	0.7
North-East	61.3	0.9	61.8	0.9	63.7	0.8	64.1	0.9	62.2	0.6	62.7	0.6
Centre	57.5	1.6	57.9	1.6	58.7	1.5	59.2	1.6	58.0	1.1	58.5	1.1
South	53.0	1.8	53.3	1.8	53.5	1.6	54.0	1.6	52.9	1.2	53.3	1.2
Pool	58.8	0.6	59.3	0.6	60.7	0.6	61.2	0.6	59.5	0.4	60.0	0.4
<b>MYELOMA</b>												
North-West	44.7	1.7	45.0	1.7	42.2	1.8	42.5	1.8	43.5	1.2	43.8	1.2
North-East	47.8	1.4	48.2	1.4	47.7	1.3	48.0	1.3	47.8	1.0	48.2	1.0
Centre	48.2	2.4	48.4	2.4	48.7	2.4	49.1	2.4	48.3	1.7	48.6	1.7
South	42.5	2.6	42.7	2.6	49.1	2.3	49.4	2.4	45.5	1.8	45.7	1.8
Pool	46.1	0.9	46.4	0.9	46.6	0.9	47.0	0.9	46.3	0.6	46.6	0.6
<b>ACUTE LYMPHATIC LEUKAEMIA</b>												
North-West	21.8	5.3	21.8	5.3	37.0	6.4	37.0	6.4	29.1	4.2	29.2	4.2
North-East	32.5	4.0	32.6	4.1	22.7	4.3	22.9	4.3	29.0	3.1	29.1	3.1
Centre	21.7	8.2	21.7	8.2	54.6	9.5	54.7	9.5	36.7	6.7	36.8	6.7
South	28.7	5.1	29.0	5.2	42.5	6.3	42.7	6.4	33.6	4.0	33.8	4.0
Pool	27.9	2.6	28.0	2.6	34.6	3.1	34.7	3.1	30.9	2.0	31.1	2.0
<b>CHRONIC LYMPHATIC LEUKAEMIA</b>												
North-West	75.6	1.9	76.4	2.0	76.4	2.0	77.0	2.0	75.5	1.4	76.2	1.4
North-East	69.4	1.7	69.8	1.7	75.3	1.7	75.8	1.7	71.8	1.2	72.3	1.2
Centre	67.5	3.2	67.6	3.2	74.5	3.2	75.1	3.2	70.6	2.3	71.0	2.3
South	70.8	2.9	71.5	3.0	69.1	3.2	69.7	3.3	70.1	2.2	70.8	2.2
Pool	71.3	1.1	71.8	1.1	74.6	1.1	75.1	1.1	72.5	0.8	73.1	0.8
<b>ACUTE MYELOID LEUKAEMIA</b>												
North-West	15.3	1.5	15.2	1.5	16.6	1.6	16.6	1.6	15.8	1.1	15.8	1.1
North-East	12.5	1.1	12.6	1.1	16.3	1.4	16.4	1.4	14.2	0.9	14.3	0.9
Centre	15.0	2.2	15.0	2.2	16.1	2.4	16.2	2.4	15.2	1.5	15.3	1.6
South	16.2	2.0	16.0	2.0	22.2	2.8	22.2	2.8	18.8	1.7	18.7	1.7
Pool	14.2	0.8	14.2	0.8	17.0	0.9	17.1	0.9	15.4	0.6	15.5	0.6
<b>CHRONIC MYELOID LEUKAEMIA</b>												
North-West	46.3	3.2	46.4	3.2	54.0	3.4	54.4	3.4	50.1	2.3	50.3	2.3
North-East	45.6	2.8	46.1	2.8	52.4	3.0	52.8	3.1	48.6	2.0	49.1	2.1
Centre	48.1	4.5	48.4	4.6	55.3	5.1	55.4	5.1	52.1	3.4	52.3	3.4
South	43.0	4.3	43.5	4.3	55.0	5.2	55.5	5.3	48.1	3.3	48.7	3.4
Pool	46.0	1.8	46.3	1.8	53.4	1.9	53.7	1.9	49.4	1.3	49.8	1.3
<b>ALL LEUKAEMIAS</b>												
North-West	48.6	1.3	48.9	1.3	44.6	1.3	44.9	1.3	46.7	0.9	46.9	0.9
North-East	45.1	1.0	45.4	1.1	44.5	1.2	44.8	1.2	45.0	0.8	45.3	0.8
Centre	41.5	1.8	41.7	1.8	43.7	2.0	44.0	2.0	42.6	1.3	42.8	1.3
South	44.8	1.7	45.3	1.7	46.6	2.0	46.9	2.0	45.5	1.3	45.9	1.3
Pool	45.5	0.7	45.8	0.7	44.8	0.7	45.1	0.8	45.2	0.5	45.5	0.5
<b>ALL BUT SKIN, NON MELANOMA</b>												
North-West	53.8	0.2	54.2	0.2	61.1	0.2	61.6	0.2	57.4	0.1	57.9	0.1
North-East	53.9	0.2	54.3	0.2	60.8	0.2	61.3	0.2	57.3	0.1	57.7	0.1
Centre	53.7	0.3	54.0	0.3	61.3	0.3	61.8	0.3	57.4	0.2	57.9	0.2
South	47.7	0.3	47.9	0.3	58.6	0.3	58.9	0.3	53.1	0.2	53.5	0.2
Pool	53.1	0.1	53.4	0.1	60.7	0.1	61.1	0.1	56.8	0.1	57.3	0.1
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>												
North-West	51.1	0.2	51.5	0.2	60.6	0.2	61.1	0.2	55.9	0.1	56.3	0.1
North-East	51.4	0.2	51.8	0.2	60.3	0.2	60.8	0.2	55.8	0.1	56.3	0.1
Centre	50.6	0.3	50.9	0.3	60.8	0.3	61.3	0.3	55.8	0.2	56.2	0.2
South	43.4	0.3	43.6	0.3	58.0	0.3	58.4	0.3	50.9	0.2	51.4	0.2
Pool	50.2	0.1	50.6	0.1	60.2	0.1	60.6	0.1	55.2	0.1	55.7	0.1

**Table 3.** Five-year age-standardized relative survival (5RS) and standard error (SE) by macroarea, gender and site. Pool of 31 cancer registries, 2000-2004. [a] Ederer II method; [b] Hakulinen method

CANCER SITE																	
Period	MALE												FEMALE				
	5RS <sup>(a)</sup> %	SE <sup>(a)</sup> %	5RS <sup>(b)</sup> %	SE <sup>(b)</sup> %	10RS <sup>(a)</sup> %	SE <sup>(a)</sup> %	10RS <sup>(b)</sup> %	SE <sup>(b)</sup> %	15RS <sup>(a)</sup> %	SE <sup>(a)</sup> %	15RS <sup>(b)</sup> %	SE <sup>(b)</sup> %	5RS <sup>(a)</sup> %	SE <sup>(a)</sup> %	5RS <sup>(b)</sup> %	SE <sup>(b)</sup> %	10RS <sup>(a)</sup> %
<b>HEAD AND NECK</b>																	
1990-1992	49.3	1.1	49.5	1.1	40.6	1.5	40.8	1.5	29.0	1.9	28.7	1.8	53.0	2.2	53.7	2.3	46.5
1993-1995	51.8	1.1	51.9	1.1	41.4	1.4	42.0	1.5					50.1	2.0	50.4	2.1	39.8
1996-1998	54.0	1.1	54.4	1.1	43.6	1.4	44.5	1.4					55.3	1.9	55.8	1.9	45.4
1999-2001	55.6	1.0	56.0	1.0	44.1	1.3	44.8	1.3					55.1	1.8	55.6	1.9	46.3
2002-2004	55.0	1.0	55.1	1.0	43.3	1.2	43.7	1.2					57.3	1.7	58.0	1.7	49.1
2005-2007	57.1	1.3	57.4	1.3	45.2	1.5	45.4	1.6	39.1	2.9	38.8	2.8	57.9	2.1	58.6	2.1	49.0
<b>SALIVARY GLANDS</b>																	
1990-1992	47.5	5.3	48.4	5.5	29.9	4.5	29.8	4.4	27.0	5.3	26.8	5.2	69.8	5.4	70.7	5.5	61.4
1993-1995	49.4	5.2	48.6	5.1	35.5	6.7	33.6	5.6					73.3	5.3	74.1	5.4	60.9
1996-1998	56.3	4.4	56.7	4.5	50.2	5.6	52.1	6.1					65.0	4.7	66.6	4.9	58.3
1999-2001	53.8	4.3	54.3	4.3	45.9	5.2	46.5	5.3					58.6	4.3	59.6	4.5	51.5
2002-2004	62.7	4.2	62.6	4.2	52.0	4.9	52.2	5.0					66.8	4.6	68.0	4.8	58.1
2005-2007	49.2	4.8	49.3	4.8	45.8	5.2	46.0	5.3					80.8	5.6	82.8	5.8	69.7
<b>OEESOPHAGUS</b>																	
1990-1992	6.7	0.9	6.9	0.9	3.9	0.8	4.2	1.0	3.1	0.7	3.1	0.7	9.3	2.1	9.3	2.1	4.7
1993-1995	9.8	1.3	10.0	1.3	7.2	1.3	7.5	1.4					17.9	3.1	18.2	3.1	14.1
1996-1998	8.7	1.0	8.7	1.0	5.8	0.9	5.8	0.9					19.3	3.0	19.4	3.0	16.6
1999-2001	10.3	1.2	10.3	1.2	7.1	1.3	7.0	1.2					10.7	2.4	10.9	2.4	8.7
2002-2004	11.0	1.2	11.0	1.2	7.1	1.1	7.0	1.1					16.8	2.8	17.0	2.8	13.8
2005-2007	12.8	1.7	12.8	1.7	12.1	2.2	11.2	1.9									
<b>STOMACH</b>																	
1990-1992	25.0	0.7	25.2	0.7	21.4	0.8	22.0	0.8	19.5	1.0	20.4	1.1	31.5	1.0	32.0	1.0	27.9
1993-1995	28.2	0.7	28.6	0.7	24.5	0.8	25.3	0.9					34.2	1.0	34.6	1.0	29.9
1996-1998	29.7	0.8	30.0	0.8	25.6	0.8	26.3	0.9					35.6	1.0	36.0	1.0	31.6
1999-2001	31.2	0.8	31.5	0.8	27.0	0.9	27.6	0.9					35.7	1.0	36.2	1.0	32.1
2002-2004	30.5	0.8	30.8	0.9	26.5	0.9	27.1	0.9					34.8	1.1	35.4	1.1	31.2
2005-2007	33.9	1.1	34.1	1.1	29.2	1.2	29.7	1.2	26.4	1.4	27.2	1.6	35.6	1.3	36.2	1.4	31.9
<b>SMALL INTESTINE</b>																	
1990-1992	38.2	4.6	38.5	4.6	39.1	5.7	40.2	6.2	27.1	4.8	26.2	4.6	35.0	4.8	35.1	4.8	23.7
1993-1995	38.5	4.4	38.9	4.5	33.5	5.8	33.5	5.7					39.3	4.3	39.4	4.3	32.3
1996-1998	40.7	3.7	40.8	3.7	35.7	4.9	35.3	4.8					41.3	4.1	41.9	4.2	38.9
1999-2001	41.5	3.6	42.1	3.7	37.9	4.5	39.1	4.8					42.0	4.0	42.9	4.1	41.8
2002-2004	47.9	3.5	47.7	3.4	45.3	4.7	45.5	4.8					57.0	3.4	57.7	3.5	57.3
2005-2007	47.5	4.1	46.9	4.0	42.7	5.8	42.5	5.6					54.2	4.4	54.8	4.5	54.7
<b>COLON</b>																	
1990-1992	52.2	0.9	52.6	0.9	47.3	1.2	48.1	1.2	44.8	1.7	45.7	1.7	52.4	0.8	52.8	0.9	47.2
1993-1995	54.6	0.8	54.9	0.8	50.6	1.1	51.5	1.1					56.2	0.8	56.6	0.8	51.9
1996-1998	57.6	0.8	57.9	0.8	53.0	1.0	53.7	1.0					58.9	0.7	59.5	0.7	53.9
1999-2001	58.8	0.7	59.2	0.7	53.3	0.9	54.0	0.9					58.5	0.7	59.0	0.7	54.2
2002-2004	60.2	0.7	60.6	0.7	55.0	0.9	55.6	0.9					61.9	0.7	62.5	0.7	57.7
2005-2007	64.2	0.8	64.6	0.8	59.7	1.1	60.3	1.1	61.0	2.0	61.9	2.1	64.2	0.8	64.8	0.8	60.1
<b>RECTUM</b>																	
1990-1992	45.5	1.1	45.8	1.2	39.4	1.4	40.1	1.4	37.1	2.0	37.8	2.1	49.1	1.2	49.6	1.2	43.5
1993-1995	48.6	1.1	49.0	1.1	43.3	1.4	44.2	1.4					52.5	1.2	53.1	1.2	46.8
1996-1998	54.5	1.0	54.9	1.1	47.7	1.3	48.5	1.3					56.8	1.1	57.4	1.1	50.9
1999-2001	55.6	1.0	56.0	1.0	47.8	1.3	48.5	1.3					57.9	1.1	58.5	1.1	51.2
2002-2004	58.5	1.0	58.9	1.0	50.4	1.3	51.0	1.3					59.0	1.1	59.6	1.1	52.1
2005-2007	63.5	1.2	64.0	1.2	56.4	1.7	57.2	1.8	51.7	3.4	52.6	3.5	61.4	1.3	62.0	1.3	54.0
<b>COLON RECTUM</b>																	
1990-1992	49.8	0.7	50.2	0.7	44.5	0.9	45.2	0.9	42.0	1.3	42.8	1.3	51.4	0.7	51.8	0.7	46.1
1993-1995	52.6	0.7	53.0	0.7	48.2	0.9	49.1	0.9					55.1	0.6	55.5	0.7	50.3
1996-1998	56.6	0.6	56.9	0.6	51.2	0.8	52.0	0.8					58.3	0.6	58.9	0.6	53.1
1999-2001	57.7	0.6	58.2	0.6	51.5	0.7	52.2	0.8					58.4	0.6	59.0	0.6	53.4
2002-2004	59.7	0.6	60.0	0.6	53.6	0.7	54.2	0.7					61.1	0.6	61.7	0.6	56.1
2005-2007	64.0	0.7	64.4	0.7	58.6	0.9	59.2	0.9	58.2	1.7	59.1	1.8	63.5	0.7	64.1	0.7	58.4
<b>LIVER</b>																	
1990-1992	7.5	0.7	7.5	0.7	3.4	0.6	3.3	0.6	3.0	0.8	2.9	0.7	10.7	1.4	10.8	1.4	4.8
1993-1995	7.9	0.7	7.9	0.7	3.4	0.5	3.4	0.5					9.2	1.2	9.2	1.2	5.4
1996-1998	12.0	0.7	12.1	0.7	5.9	0.6	6.0	0.6					13.2	1.3	13.3	1.3	6.8
1999-2001	12.7	0.7	12.8	0.7	6.3	0.6	6.4	0.6					14.8	1.4	15.1	1.4	7.1
2002-2004	16.3	0.8	16.5	0.8	8.1	0.7	8.2	0.7					16.2	1.4	16.4	1.4	8.8
2005-2007	17.2	1.0	17.4	1.0	8.8	0.9	8.9	1.0					16.3	1.6	16.5	1.6	8.2

**Table 4.** Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site.  
Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

							MALE & FEMALE												
SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	
2.6	48.2	2.8	37.0	3.0	38.8	3.4	50.0	1.0	50.4	1.0	41.5	1.3	42.3	1.3	30.6	1.5	31.0	1.6	
2.4	40.6	2.5					51.4	1.0	51.6	1.0	41.4	1.2	41.9	1.2					
2.1	46.1	2.2					53.8	0.9	54.3	0.9	43.4	1.1	44.1	1.2					
2.2	47.2	2.3					55.1	0.9	55.5	0.9	44.5	1.1	45.2	1.1					
2.2	50.1	2.3					55.5	0.9	55.8	0.9	44.6	1.0	45.1	1.1					
2.7	49.9	2.8	43.1	4.3	44.9	4.7	57.4	1.1	57.8	1.1	46.2	1.3	46.5	1.4	40.2	2.5	40.2	2.5	
7.0	63.6	7.6	61.3	10.5	65.6	12.5	56.7	3.9	57.8	4.1	44.0	4.3	46.0	4.8	42.4	6.1	46.6	7.9	
7.1	61.4	7.2					59.5	3.8	59.8	3.9	46.9	4.9	46.9	4.8					
5.5	60.8	6.0					60.8	3.2	61.9	3.3	53.7	3.9	56.2	4.3					
5.0	53.9	5.7					55.8	3.1	56.6	3.1	48.0	3.6	49.5	3.9					
5.3	60.9	6.1					64.2	3.1	64.6	3.1	53.7	3.6	54.8	3.8					
8.7	75.2	10.9	65.4	12.1	72.2	15.9	61.1	4.0	61.7	4.1	51.6	4.5	52.6	4.7	47.8	6.5	50.2	7.1	
1.7	4.7	1.7	3.5	1.5	3.5	1.5	6.9	0.8	6.9	0.8	3.9	0.7	3.9	0.7	3.0	0.6	3.0	0.6	
3.0	14.5	3.1					11.2	1.1	11.5	1.2	8.1	1.1	8.5	1.2					
3.0	16.7	3.0					10.6	1.0	10.6	1.0	7.8	1.0	7.8	1.0					
2.1	9.6	2.3					10.4	1.0	10.5	1.0	7.5	1.2	7.6	1.2					
2.6	14.4	2.7					12.1	1.1	12.2	1.1	8.6	1.1	8.7	1.1					
							13.9	1.5	14.0	1.6	12.3	1.8	12.4	1.8	11.9	2.3	13.6	2.8	
1.0	28.9	1.1	25.7	1.1	26.9	1.2	27.5	0.6	27.9	0.6	23.9	0.6	24.9	0.7	21.7	0.7	23.2	0.8	
1.0	30.5	1.0					30.4	0.6	30.8	0.6	26.5	0.6	27.3	0.7					
1.0	32.4	1.1					32.2	0.6	32.6	0.6	28.2	0.6	29.1	0.7					
1.1	32.9	1.1					32.9	0.6	33.4	0.6	29.0	0.7	29.8	0.7					
1.1	32.1	1.1					32.0	0.7	32.5	0.7	28.2	0.7	29.0	0.7					
1.4	32.9	1.4	28.5	1.5	29.5	1.6	34.2	0.8	34.7	0.8	30.0	0.9	30.9	0.9	26.8	1.0	28.0	1.1	
4.5	23.9	4.6	26.2	5.7	27.8	6.4	37.0	3.3	37.1	3.3	31.8	3.6	32.0	3.7	28.1	4.0	28.5	4.4	
4.9	32.4	4.9					38.4	3.0	38.6	3.0	32.6	3.7	32.7	3.7					
4.4	40.3	4.7					40.3	2.7	40.7	2.7	35.8	3.2	36.4	3.2					
4.5	45.2	5.0					41.9	2.6	42.7	2.7	39.7	3.1	42.1	3.5					
4.1	59.9	4.5					52.0	2.5	52.2	2.5	49.9	3.2	51.4	3.3					
5.0	57.2	5.5	39.2	7.1	41.8	8.6	50.3	2.9	50.4	2.9	48.1	3.7	49.5	3.9	44.4	6.1	47.4	7.1	
1.0	47.9	1.0	44.4	1.2	45.3	1.3	52.2	0.6	52.6	0.6	47.2	0.7	48.0	0.8	44.6	1.0	45.5	1.0	
0.9	52.6	0.9					55.4	0.6	55.8	0.6	51.2	0.7	52.0	0.7					
0.9	54.7	0.9					58.1	0.5	58.6	0.5	53.4	0.6	54.1	0.7					
0.8	54.9	0.9					58.6	0.5	59.0	0.5	53.6	0.6	54.3	0.6					
0.8	58.6	0.9					60.9	0.5	61.4	0.5	56.3	0.6	57.0	0.6					
1.0	61.0	1.0	58.4	1.5	59.4	1.6	64.1	0.6	64.6	0.6	59.9	0.7	60.7	0.8	59.3	1.2	60.3	1.2	
1.4	44.6	1.4	40.1	1.7	41.3	1.8	47.2	0.8	47.7	0.8	41.4	1.0	42.4	1.0	38.4	1.2	39.6	1.3	
1.3	47.9	1.4					50.3	0.8	50.8	0.8	44.9	1.0	46.0	1.0					
1.3	52.1	1.4					55.4	0.8	55.9	0.8	49.1	0.9	50.2	1.0					
1.2	52.3	1.3					56.4	0.7	56.9	0.7	49.0	0.9	50.0	0.9					
1.2	53.2	1.3					58.6	0.7	59.1	0.7	51.0	0.9	51.9	0.9					
1.6	55.3	1.6	52.3	2.2	54.1	2.4	62.5	0.9	63.1	0.9	55.1	1.1	56.2	1.2	52.3	1.8	54.0	2.0	
0.8	46.9	0.8	43.1	1.0	44.1	1.1	50.5	0.5	51.0	0.5	45.3	0.6	46.1	0.6	42.5	0.8	43.5	0.8	
0.8	51.2	0.8					53.8	0.5	54.2	0.5	49.1	0.6	50.0	0.6					
0.7	54.0	0.7					57.3	0.4	57.8	0.4	52.1	0.5	52.9	0.5					
0.7	54.3	0.7					57.9	0.4	58.4	0.4	52.2	0.5	53.0	0.5					
0.7	57.1	0.7					60.3	0.4	60.7	0.4	54.7	0.5	55.5	0.5					
0.9	59.4	0.9	56.6	1.2	57.9	1.3	63.6	0.5	64.1	0.5	58.4	0.6	59.3	0.6	57.1	1.0	58.3	1.1	
1.1	4.8	1.1	3.2	1.0	3.1	1.0	8.3	0.6	8.4	0.7	3.8	0.5	3.8	0.5	3.0	0.6	3.0	0.5	
1.0	5.5	1.0					8.2	0.6	8.2	0.6	3.9	0.4	4.0	0.5					
1.1	7.0	1.1					12.1	0.6	12.2	0.6	6.0	0.5	6.1	0.5					
1.2	7.3	1.2					13.4	0.6	13.6	0.6	6.6	0.5	6.7	0.5					
1.2	9.0	1.2					16.3	0.7	16.4	0.7	8.1	0.6	8.2	0.6					
1.4	8.3	1.4					17.2	0.9	17.3	0.9	8.6	0.8	8.7	0.8	5.9	0.9	6.2	1.0	

**Table 4.** Five, 10,15-year age-standardized relative survival (5RS,10RS,15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF>>

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																	
Period	MALE												FEMALE				
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %
<b>BILIARY TRACT</b>																	
1990-1992	11.4	1.4	11.5	1.4	9.6	1.6	10.0	1.7	8.0	1.8	8.6	2.0	10.3	1.4	10.3	1.4	8.1
1993-1995	13.9	1.8	14.0	1.8	8.2	1.6	8.2	1.6					10.4	1.2	10.5	1.2	8.9
1996-1998	17.2	1.9	17.4	1.9	14.1	2.0	14.4	2.0					13.9	1.7	14.0	1.7	12.5
1999-2001	15.0	1.6	15.3	1.7	12.0	1.6	12.8	1.7					12.6	1.2	12.8	1.2	
2002-2004	19.5	1.7	19.7	1.7	15.9	1.9	16.5	1.9					18.1	1.7	18.3	1.7	
2005-2007	20.5	2.3	20.7	2.3	18.0	2.6	18.6	2.6	18.3	3.9	19.1	4.2	17.9	2.3	18.2	2.3	
<b>PANCREAS</b>																	
1990-1992	4.0	0.7	4.0	0.7	3.4	0.7	3.4	0.7	2.6	0.6	2.7	0.6	5.7	0.8	5.8	0.8	4.8
1993-1995	4.0	0.6	4.0	0.6	3.1	0.6	3.0	0.5					6.3	0.9	6.3	0.9	5.1
1996-1998	5.1	0.6	5.1	0.6	4.1	0.7	4.1	0.7					7.6	0.9	7.6	0.9	6.0
1999-2001	4.8	0.6	4.9	0.6	4.0	0.6	4.1	0.6					7.6	0.8	7.7	0.8	5.6
2002-2004	6.3	0.6	6.4	0.6	5.5	0.6	5.6	0.7					9.1	0.8	9.1	0.8	6.7
2005-2007	7.0	0.8	7.1	0.8	5.9	0.8	5.9	0.8					8.8	1.1	8.8	1.1	6.6
<b>LARYNX</b>																	
1990-1992	65.0	1.5	65.1	1.5	55.3	2.1	55.2	2.1	41.6	2.8	40.9	2.7	72.5	4.5	72.5	4.5	63.4
1993-1995	67.7	1.6	67.8	1.6	55.9	2.1	56.3	2.2					70.7	4.2	71.2	4.3	60.0
1996-1998	69.0	1.5	69.5	1.5	57.7	2.0	58.2	2.1					64.0	3.7	64.0	3.7	52.2
1999-2001	68.6	1.4	69.0	1.4	57.5	1.9	58.1	2.0					74.3	3.9	74.8	4.0	62.0
2002-2004	69.1	1.4	69.3	1.4	57.4	1.8	57.8	1.9					72.3	3.8	72.6	3.8	60.9
2005-2007	70.0	1.8	70.2	1.8	57.7	2.4	58.0	2.4	50.0	4.8	49.2	4.5	67.8	4.5	68.2	4.5	52.2
<b>LUNG</b>																	
1990-1992	10.3	0.3	10.3	0.3	7.2	0.3	7.3	0.3	5.7	0.4	5.8	0.4	11.9	0.7	11.9	0.7	9.5
1993-1995	11.3	0.3	11.3	0.3	8.0	0.3	8.1	0.3					13.3	0.7	13.4	0.7	9.4
1996-1998	12.1	0.3	12.2	0.4	8.1	0.3	8.2	0.3					15.6	0.7	15.7	0.7	11.9
1999-2001	12.3	0.4	12.4	0.4	8.6	0.3	8.8	0.4					16.2	0.7	16.3	0.7	11.9
2002-2004	13.2	0.4	13.3	0.4	9.5	0.4	9.7	0.4					17.0	0.7	17.2	0.7	12.8
2005-2007	13.7	0.5	13.8	0.5	10.0	0.5	10.2	0.5	7.6	0.6	7.9	0.7	18.2	0.8	18.4	0.8	13.9
<b>BONE</b>																	
1990-1992	39.7	5.5	40.1	5.6	37.6	6.1	38.3	6.3	33.6	6.4	33.8	6.5	64.5	5.4	64.4	5.4	59.7
1993-1995	49.4	4.4	49.8	4.5	43.9	4.7	44.4	4.8					56.9	5.6	57.3	5.6	45.2
1996-1998	56.7	6.0	56.1	5.8	50.5	6.8	51.2	7.2					55.9	5.2	56.3	5.2	53.0
1999-2001	55.9	4.3	56.1	4.3									51.1	5.5	51.1	5.5	
2002-2004	53.1	4.6	53.3	4.6									63.4	5.1	63.8	5.2	63.4
2005-2007	57.3	5.5	57.4	5.6									58.2	5.4	58.4	5.5	58.9
<b>SKIN MELANOMA</b>																	
1990-1992	70.5	1.8	70.7	1.9	61.5	2.3	61.8	2.3	63.6	3.5	64.4	3.7	82.6	1.4	82.7	1.4	76.0
1993-1995	74.7	1.5	74.9	1.5	69.4	2.1	69.8	2.1					84.5	1.2	84.7	1.2	81.0
1996-1998	81.2	1.3	81.4	1.3	75.7	1.7	76.0	1.8					86.3	1.0	86.5	1.0	82.8
1999-2001	81.3	1.1	81.4	1.1	76.6	1.5	77.0	1.5					87.4	0.9	87.6	1.0	84.5
2002-2004	81.9	1.1	82.0	1.1	77.6	1.5	78.0	1.5					89.2	0.8	89.6	0.9	85.9
2005-2007	83.6	1.2	83.8	1.2	79.6	1.8	80.2	1.9	80.7	3.3	81.3	3.4	89.3	1.0	89.6	1.1	85.2
<b>MESOTHELIOMA</b>																	
1990-1992	7.7	2.3	7.5	2.2	3.4	1.3	3.4	1.3	3.2	1.4	3.2	1.3	8.1	3.1	8.2	3.1	4.2
1993-1995	5.4	1.6	5.5	1.7	1.0	0.7	1.0	0.7					10.6	3.1	10.9	3.2	4.0
1996-1998	9.8	2.0	9.9	2.0	5.5	1.6	5.5	1.6					8.9	2.9	9.1	3.0	5.0
1999-2001	6.7	1.4	6.9	1.5									11.0	2.6	11.0	2.6	4.5
2002-2004	9.6	1.8	9.8	1.9									11.2	2.8	11.2	2.8	3.5
2005-2007	10.2	2.6	10.3	2.6									9.6	3.1	9.7	3.2	
<b>KAPOSI SARCOMA</b>																	
1990-1992	68.9	4.9	68.6	4.8	58.4	6.8	58.6	6.9	42.9	7.3	43.0	7.4	83.5	5.6	83.9	5.6	70.3
1993-1995	69.8	4.8	69.7	4.8	60.9	7.6	59.7	7.3					80.9	5.6	80.3	5.5	69.3
1996-1998	75.8	4.3	75.6	4.3	68.4	6.8	67.9	6.7					79.2	5.5	79.9	5.5	66.4
1999-2001	80.0	3.9	80.0	3.9	76.4	5.7	75.6	5.6					89.4	4.7	89.4	4.7	74.1
2002-2004	91.9	3.8	91.7	3.8	86.4	6.3	85.2	6.1					92.0	4.6	91.3	4.5	80.2
2005-2007	89.8	4.7	88.7	4.6	84.1	7.1	81.9	6.6	82.0	17.9	78.1	16.1	82.6	4.7	82.4	4.7	83.8
<b>SOFT TISSUE</b>																	
1990-1992	59.4	3.5	59.4	3.5	55.3	4.4	55.2	4.4	47.6	5.1	48.0	5.4	57.7	3.3	58.0	3.3	52.8
1993-1995	54.8	3.1	54.7	3.1	52.7	4.1	51.1	3.7					58.1	3.3	58.4	3.3	51.4
1996-1998	61.6	2.9	61.7	2.9	52.3	3.3	52.2	3.3					63.0	2.9	63.2	2.9	59.8
1999-2001	60.8	2.7	61.2	2.7	53.5	3.0	53.8	3.0					58.3	2.8	58.8	2.9	53.7
2002-2004	63.7	2.6	63.9	2.6	56.0	3.0	56.1	3.0					68.0	2.6	68.3	2.6	62.3
2005-2007	67.9	3.0	67.9	3.0	60.7	3.7	61.0	3.7	67.6	6.5	67.8	6.7	73.1	3.1	73.7	3.1	66.1

Table 4. Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site.

CONTINUED OVERLEAF&gt;&gt;

Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method



							MALE & FEMALE												
SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	
1.3	8.3	1.4	8.1	1.5	8.6	1.6	10.7	1.0	10.8	1.0	8.6	1.0	8.8	1.0	8.2	1.1	8.6	1.2	
1.2	9.1	1.2					11.7	1.0	11.8	1.0	8.8	1.0	8.9	1.0					
1.7	12.7	1.7					15.4	1.3	15.5	1.3	13.2	1.3	13.4	1.3					
							13.8	1.0	14.0	1.0	11.4	1.0	11.9	1.1					
							18.8	1.2	19.0	1.2	15.8	1.3	16.3	1.3					
							19.0	1.6	19.3	1.6	16.4	1.6	17.0	1.6	14.4	1.9	15.0	2.0	
0.8	4.9	0.8	4.3	0.8	4.6	0.9	4.7	0.5	4.8	0.5	4.0	0.5	4.1	0.5	3.5	0.5	3.7	0.6	
0.8	5.1	0.8					4.9	0.5	4.9	0.5	3.8	0.5	3.7	0.5					
0.8	6.1	0.8					5.9	0.5	6.0	0.5	4.7	0.5	4.8	0.5					
0.7	5.7	0.7					6.1	0.5	6.2	0.5	4.7	0.5	4.9	0.5					
0.8	6.8	0.8					7.5	0.5	7.5	0.5	5.9	0.5	6.1	0.5					
1.0	6.7	1.1					7.9	0.7	7.9	0.7	6.1	0.7	6.3	0.7					
5.7	64.0	5.8	46.3	6.0	46.8	6.5	65.5	1.5	65.7	1.5	55.7	2.0	55.9	2.0	41.7	2.5	41.3	2.5	
5.4	60.7	5.6					68.1	1.5	68.2	1.5	56.5	2.0	56.9	2.0					
4.3	52.4	4.4					68.6	1.4	68.9	1.4	56.9	1.9	57.3	1.9					
5.1	63.0	5.2					69.2	1.3	69.5	1.4	57.8	1.8	58.5	1.8					
4.9	61.7	5.1					69.6	1.3	69.8	1.3	57.8	1.7	58.3	1.7					
5.5	52.6	5.6	46.6	9.7	47.3	10.1	69.9	1.7	70.1	1.7	57.2	2.2	57.5	2.2	50.3	4.3	49.7	4.2	
0.7	9.7	0.7	8.4	0.8	8.5	0.8	10.6	0.3	10.7	0.3	7.7	0.3	7.8	0.3	6.2	0.3	6.4	0.4	
0.7	9.5	0.7					11.7	0.3	11.8	0.3	8.3	0.3	8.4	0.3					
0.7	12.2	0.7					12.8	0.3	12.9	0.3	8.9	0.3	9.1	0.3					
0.6	12.1	0.6					13.4	0.3	13.5	0.3	9.5	0.3	9.7	0.3					
0.6	13.1	0.7					14.1	0.3	14.3	0.3	10.2	0.3	10.5	0.3					
0.8	14.1	0.9	11.2	1.0	11.5	1.1	15.1	0.4	15.2	0.4	11.1	0.4	11.3	0.4	8.7	0.5	9.0	0.6	
8.1	60.0	8.2	51.9	12.3	53.1	13.3	48.3	4.1	48.6	4.1	44.5	4.7	45.4	4.9	38.7	5.6	39.6	6.1	
5.9	46.5	6.2					53.1	3.5	53.7	3.6	45.4	3.8	46.7	4.1					
5.2	53.5	5.3					55.8	3.8	55.6	3.8	51.5	4.1	51.7	4.1					
							54.3	3.3	54.4	3.3									
5.5	64.3	5.8					56.9	3.5	57.2	3.6	53.8	4.0	54.5	4.2					
5.9	59.4	6.1	57.5	6.4	57.7	6.5	57.3	4.1	57.4	4.1	54.3	5.0	54.6	5.1					
1.8	76.7	1.8	73.5	2.3	74.7	2.5	77.1	1.1	77.3	1.1	69.6	1.4	70.3	1.5	68.4	1.9	70.1	2.1	
1.6	81.5	1.6					80.0	0.9	80.2	0.9	75.7	1.3	76.4	1.3					
1.3	83.2	1.4					83.8	0.8	84.0	0.8	79.4	1.1	80.0	1.1					
1.3	85.1	1.3					84.5	0.7	84.7	0.7	80.8	1.0	81.6	1.0					
1.2	86.7	1.2					85.5	0.7	85.8	0.7	81.9	0.9	82.6	1.0					
1.5	85.9	1.5	82.1	2.3	82.8	2.4	86.3	0.8	86.7	0.8	82.4	1.1	83.2	1.2	80.6	1.9	81.7	2.0	
2.4	4.3	2.4	4.7	2.7	4.8	2.8	7.5	1.8	7.4	1.7	3.7	1.2	3.7	1.2	3.7	1.3	3.8	1.3	
2.5	4.6	2.9					7.1	1.5	7.3	1.6	2.1	1.0	2.4	1.3					
2.2	5.4	2.5					9.4	1.7	9.6	1.7	5.5	1.4	5.7	1.5					
2.3	4.8	2.4					7.9	1.3	8.0	1.3	4.0	1.0	4.1	1.1					
2.0	3.6	2.1					10.1	1.5	10.2	1.5	4.4	1.2	4.5	1.2					
							8.9	1.7	9.0	1.8	2.9	1.2	2.9	1.2					
8.4	73.2	8.9	68.5	11.5	76.4	13.6	71.5	3.8	71.6	3.8	61.0	5.1	62.7	5.4	54.1	6.7	57.4	7.6	
8.0	68.8	7.9					70.9	3.7	70.5	3.7	60.0	5.2	59.3	5.1					
6.6	67.5	6.8					76.3	3.4	76.5	3.5	65.9	4.9	66.3	4.9					
7.4	74.6	7.5					83.0	3.0	83.2	3.0	76.3	4.4	76.4	4.4					
7.6	80.2	7.6					92.1	3.0	92.0	3.0	84.8	4.9	84.4	4.9					
7.9	83.8	7.9	98.4	19.0	104.4	21.3	89.5	3.6	89.0	3.6	86.2	5.7	85.1	5.5	86.8	13.6	87.3	13.8	
3.6	53.5	3.7	51.5	4.3	53.0	4.7	58.6	2.4	58.8	2.4	54.4	2.8	54.7	2.9	50.4	3.3	51.5	3.6	
3.5	52.1	3.6					56.6	2.2	56.8	2.2	51.8	2.5	52.0	2.5					
3.2	60.5	3.2					61.9	2.1	62.0	2.1	55.7	2.3	55.8	2.3					
3.1	54.6	3.1					59.5	1.9	59.9	2.0	53.7	2.1	54.2	2.2					
3.0	63.2	3.1					65.8	1.8	65.9	1.8	59.2	2.2	59.6	2.2					
3.8	67.1	3.9	67.3	4.9	70.6	5.8	69.6	2.2	69.8	2.2	63.0	2.6	63.5	2.7	64.8	3.8	66.9	4.3	

**Table 4.** Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Period	MALE												FEMALE					
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	
<b>BREAST</b>																		
1990-1992														78.4	0.5	78.7	0.5	68.0
1993-1995														80.2	0.5	80.6	0.5	69.0
1996-1998														83.1	0.4	83.3	0.4	73.8
1999-2001														84.8	0.4	85.2	0.4	75.5
2002-2004														85.6	0.4	85.8	0.4	76.6
2005-2007														86.9	0.4	87.1	0.4	77.9
<b>CERVIX UTERI</b>																		
1990-1992														62.6	1.4	62.8	1.4	56.8
1993-1995														66.6	1.3	66.8	1.3	60.2
1996-1998														66.7	1.3	67.0	1.3	61.1
1999-2001														66.6	1.4	66.8	1.4	60.9
2002-2004														68.2	1.4	68.5	1.4	62.1
2005-2007														71.3	1.7	71.6	1.8	65.6
<b>CORPUS UTERI</b>																		
1990-1992														73.5	1.1	73.8	1.1	68.0
1993-1995														74.3	1.0	74.8	1.1	71.3
1996-1998														74.5	1.0	74.7	1.0	68.8
1999-2001														76.4	0.9	77.0	0.9	71.1
2002-2004														76.4	0.9	77.0	0.9	71.0
2005-2007														77.1	1.0	77.5	1.1	70.4
<b>OVARY</b>																		
1990-1992														32.7	1.2	32.9	1.2	25.9
1993-1995														34.2	1.1	34.4	1.1	28.0
1996-1998														33.6	1.0	34.0	1.0	26.1
1999-2001														36.8	1.0	37.0	1.0	29.2
2002-2004														39.2	1.0	39.5	1.0	31.0
2005-2007														37.3	1.2	37.5	1.2	29.9
<b>PROSTATE</b>																		
1990-1992	62.0	1.2	62.1	1.2	49.3	1.4	49.7	1.4	40.7	2.0	41.4	2.0						
1993-1995	69.8	1.0	70.0	1.0	56.9	1.2	57.3	1.2										
1996-1998	78.5	0.7	78.7	0.7	66.6	1.0	67.1	1.0										
1999-2001	85.1	0.6	85.3	0.6	75.9	0.9	76.3	0.9										
2002-2004	88.9	0.4	89.1	0.4	80.1	0.8	80.5	0.8										
2005-2007	90.8	0.5	91.0	0.5	81.7	1.0	82.0	1.0	73.0	1.9	73.6	2.0						
<b>TESTIS</b>																		
1990-1992	86.2	2.5	86.5	2.6	85.3	3.2	85.6	3.3	80.7	2.9	81.0	3.0						
1993-1995	89.6	3.1	89.8	3.2	89.4	4.6	90.9	5.2										
1996-1998	89.1	2.6	88.8	2.5	85.6	3.5	85.1	2.9										
1999-2001	91.0	2.5	92.8	3.0	87.7	3.4	88.8	4.1										
2002-2004	92.0	2.3	92.0	2.3	90.6	4.1	90.5	3.9										
2005-2007	93.5	3.1	94.4	3.3	88.1	3.8	88.5	4.1	90.6	15.5	87.7	10.2						
<b>KIDNEY</b>																		
1990-1992	58.5	1.5	58.8	1.5	52.7	2.0	53.5	2.1	50.4	3.2	52.4	3.6	63.5	1.8	63.8	1.8	58.5	
1993-1995	62.4	1.4	62.9	1.4	55.0	1.8	55.9	1.9					63.0	1.5	63.6	1.5	57.7	
1996-1998	63.1	1.2	63.9	1.2	57.6	1.6	59.0	1.7					66.8	1.4	67.3	1.4	60.9	
1999-2001	66.3	1.1	66.7	1.2	58.7	1.5	59.4	1.5					69.5	1.3	70.2	1.3	63.3	
2002-2004	69.4	1.1	70.1	1.1	62.2	1.5	63.3	1.6					70.7	1.2	71.3	1.3	64.0	
2005-2007	69.3	1.3	70.2	1.3	59.7	1.8	60.8	1.9	55.6	3.1	56.8	3.3	72.7	1.5	73.2	1.5	66.0	
<b>URINARY TRACT</b>																		
1990-1992	56.5	2.7	56.9	2.7	44.3	3.1	45.0	3.3	39.0	4.2	40.8	4.8	49.9	3.8	49.9	3.8	44.9	
1993-1995	58.8	2.5	58.9	2.5	52.6	3.1	53.1	3.2					46.0	3.9	45.9	3.9	37.1	
1996-1998	61.8	2.6	62.1	2.7	55.1	3.3	56.0	3.4					63.0	4.1	63.8	4.2	56.7	
1999-2001	64.3	2.6	64.9	2.6	55.8	3.0	57.3	3.2					52.3	3.9	52.5	3.9	46.6	
2002-2004	62.3	2.6	63.2	2.6	55.6	3.1	57.4	3.3					55.4	4.1	55.7	4.1	48.3	
2005-2007	64.6	3.3	65.1	3.3	55.7	4.1	57.2	4.3	48.8	5.6	49.7	5.9						
<b>URINARY BLADDER</b>																		
1990-1992	71.5	0.7	71.9	0.8	60.8	1.0	61.6	1.0	53.5	1.4	54.9	1.5	74.0	1.3	74.8	1.4	67.8	
1993-1995	73.1	0.7	73.5	0.7	64.7	1.0	65.7	1.0					73.0	1.2	73.4	1.2	64.8	
1996-1998	75.8	0.6	76.2	0.6	67.0	0.9	68.0	0.9					75.9	1.1	76.4	1.1	69.2	
1999-2001	77.0	0.6	77.5	0.6	67.9	0.8	68.7	0.8					77.0	1.0	77.8	1.1	70.7	
2002-2004	79.3	0.6	79.8	0.6	69.9	0.8	70.8	0.8					77.5	1.0	78.2	1.1	72.3	
2005-2007	79.9	0.7	80.4	0.7	70.0	1.0	70.8	1.0	59.2	1.6	60.3	1.8	79.6	1.2	80.6	1.2	75.1	

Table 4. Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site.

CONTINUED OVERLEAF&gt;&gt;

Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

							MALE & FEMALE												
SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	
0.7	68.7	0.7	60.6	1.0	61.6	1.0													
0.6	69.9	0.7																	
0.6	74.4	0.6																	
0.5	76.3	0.5																	
0.5	77.2	0.5																	
0.7	78.6	0.7	70.3	1.1	71.4	1.2													
1.5	57.2	1.6	54.8	1.8	55.5	1.9													
1.5	60.6	1.5																	
1.5	61.7	1.6																	
1.5	61.5	1.6																	
1.6	62.6	1.6																	
1.9	66.3	2.0	61.1	2.1	61.6	2.2													
1.5	68.8	1.5	63.1	2.0	64.9	2.2													
1.4	72.4	1.5																	
1.3	69.3	1.3																	
1.2	72.1	1.2																	
1.2	72.0	1.2																	
1.4	71.4	1.5	68.5	2.3	69.4	2.4													
1.2	26.2	1.3	24.9	1.6	25.3	1.6													
1.1	28.2	1.2																	
1.0	26.6	1.0																	
1.0	29.6	1.1																	
1.1	31.4	1.1																	
1.3	30.3	1.3	27.6	1.6	28.2	1.7													
2.2	58.7	2.3	51.3	2.8	51.6	2.8	60.2	1.1	60.6	1.1	54.8	1.5	55.5	1.5	49.8	2.1	50.8	2.2	
1.8	58.9	1.9					62.4	1.0	62.9	1.0	55.6	1.3	56.8	1.3					
1.7	62.2	1.8					64.3	0.9	64.9	0.9	58.6	1.1	60.0	1.2					
1.6	65.1	1.7					67.4	0.8	68.0	0.9	60.4	1.1	61.7	1.1					
1.6	65.6	1.7					69.9	0.8	70.5	0.8	62.8	1.1	64.2	1.1					
1.9	67.6	2.0	63.7	3.2	66.4	3.7	70.4	1.0	71.1	1.0	62.1	1.3	63.5	1.4	58.5	2.2	60.5	2.5	
4.3	45.3	4.3	44.1	5.3	45.6	5.7	54.2	2.2	54.3	2.2	44.5	2.5	44.9	2.6	41.3	3.3	42.7	3.6	
4.1	37.2	4.1					55.5	2.1	55.5	2.1	48.4	2.5	48.4	2.5					
4.8	59.2	5.1					61.7	2.2	62.4	2.3	55.6	2.7	57.3	2.9					
4.3	47.5	4.4					60.9	2.1	61.2	2.1	53.3	2.5	54.5	2.6					
4.5	49.5	4.7					61.1	2.2	61.7	2.2	54.6	2.5	56.2	2.7					
							62.6	2.7	63.1	2.7	55.3	3.3	56.7	3.5	50.7	5.1	53.2	5.8	
1.7	69.1	1.8	63.4	2.3	65.4	2.5	71.9	0.7	72.4	0.7	62.2	0.9	63.2	0.9	55.7	1.2	57.4	1.3	
1.5	65.7	1.6					73.1	0.6	73.4	0.6	64.5	0.8	65.4	0.8					
1.4	70.4	1.5					75.7	0.5	76.1	0.5	67.4	0.7	68.4	0.8					
1.4	72.2	1.4					76.9	0.5	77.4	0.5	68.4	0.7	69.3	0.7					
1.4	73.8	1.4					78.8	0.5	79.4	0.5	70.4	0.7	71.4	0.7					
1.7	76.9	1.7	68.7	2.5	70.7	2.7	79.7	0.6	80.3	0.6	71.0	0.9	72.0	0.9	61.2	1.4	62.4	1.5	

Table 4. Five, 10,15-year age-standardized relative survival (5RS,10RS,15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF>>

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																		
Period	MALE												FEMALE					
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	
<b>CHOROID MELANOMA</b>																		
1990-1992	83.7	12.5	84.1	12.7	73.7	22.4	74.7	23.1	18.5	9.2	19.1	9.7	65.4	15.4	66.4	15.7	36.3	
1993-1995	85.4	17.8	85.4	17.8	135.3	37.9	135.0	37.7					95.6	8.5	97.1	9.0	60.6	
1996-1998	75.1	14.7	70.6	12.6	67.2	27.7	55.8	18.3					90.2	8.9	89.8	8.7	98.3	
1999-2001	95.4	9.5	95.1	9.4									85.5	7.6	87.3	8.0	74.8	
2005-2007	90.2	10.9	91.8	11.0									89.6	6.9	90.2	7.0		
2005-2007													71.2	9.8	71.8	10.0		
<b>BRAIN AND CENTRAL NERVOUS SYSTEM</b>																		
1990-1992	18.0	1.3	17.9	1.3	12.8	1.2	12.7	1.2	11.0	1.8	10.4	1.4	23.4	1.6	23.4	1.6	19.3	
1993-1995	21.2	1.3	21.3	1.3	15.1	1.3	15.3	1.3					21.8	1.6	21.8	1.6	17.3	
1996-1998	18.7	1.2	18.7	1.2	14.2	1.2	14.2	1.2					22.9	1.4	22.9	1.4	18.0	
1999-2001	20.9	1.2	20.9	1.2	15.4	1.2	15.5	1.2					25.0	1.5	25.0	1.5	19.4	
2002-2004	21.9	1.2	22.0	1.2	15.9	1.2	16.0	1.2					26.9	1.5	26.9	1.5	21.4	
2005-2007	20.7	1.5	20.7	1.5	15.4	1.4	15.4	1.4	13.0	1.5	13.1	1.5	28.3	2.0	28.4	2.0	22.0	
<b>THYROID</b>																		
1990-1992	66.9	2.4	67.0	2.4	60.2	2.7	60.3	2.7	58.0	3.2	58.2	3.2	80.5	1.5	80.8	1.5	77.0	
1993-1995	75.7	2.6	76.0	2.6	68.3	3.1	68.9	3.3					84.1	1.2	84.4	1.2	81.0	
1996-1998	83.1	2.3	83.2	2.3	77.2	3.0	78.1	3.2					89.2	1.0	89.4	1.0	87.6	
1999-2001	89.0	1.8	89.1	1.8	83.8	2.7	84.5	2.8					90.6	0.9	91.1	0.9	88.2	
2002-2004	89.2	1.6	89.5	1.6	84.8	2.5	85.6	2.6					92.7	0.8	93.1	0.8	91.1	
2005-2007	90.9	1.7	91.0	1.7	88.0	3.2	88.6	3.3	87.6	6.8	91.3	8.3	96.5	0.8	96.9	0.8	95.9	
<b>HODGKIN LYMPHOMA</b>																		
1990-1992	75.1	2.3	75.2	2.3	70.8	2.8	71.1	3.0	64.8	2.4	64.7	2.4	81.3	2.0	81.4	2.0	73.1	
1993-1995	79.2	2.6	79.5	2.7	71.3	3.4	71.4	3.5					80.0	1.9	80.1	1.9	74.3	
1996-1998	80.6	1.8	80.8	1.8	75.2	2.2	75.7	2.3					82.3	2.0	82.6	2.1	76.3	
1999-2001	81.0	1.8	81.4	1.9	72.0	1.9	72.3	2.0					85.5	1.8	85.6	1.8	81.6	
2002-2004	80.0	1.9	80.2	1.9	72.9	1.8	73.1	1.9					84.3	2.0	84.6	2.0	80.8	
2005-2007	75.1	2.0	75.1	2.0	69.4	2.2	69.4	2.2					88.6	2.1	88.9	2.1	84.2	
<b>NON HODGKIN LYMPHOMA</b>																		
1990-1992	46.6	1.4	47.0	1.4	36.7	1.6	37.4	1.7	28.8	2.0	29.6	2.2	53.7	1.2	54.1	1.3	43.3	
1993-1995	49.1	1.3	49.4	1.3	40.5	1.6	41.0	1.6					54.2	1.1	54.7	1.1	43.9	
1996-1998	54.9	1.2	55.2	1.2	45.0	1.4	45.4	1.4					58.1	1.1	58.6	1.1	48.3	
1999-2001	57.7	1.1	58.2	1.1	48.1	1.4	49.0	1.4					60.2	1.0	60.8	1.0	51.6	
2002-2004	60.7	1.1	61.4	1.1	51.1	1.3	52.1	1.4					62.4	1.0	62.9	1.0	53.8	
2005-2007	62.5	1.3	63.0	1.3	52.7	1.7	53.7	1.8	41.6	3.0	42.5	3.2	66.8	1.2	67.5	1.2	57.9	
<b>MYELOMA</b>																		
1990-1992	36.1	2.2	36.2	2.2	23.7	2.4	23.7	2.4	16.8	3.3	17.2	3.4	38.0	2.0	38.3	2.1	19.7	
1993-1995	39.0	1.8	39.4	1.9	22.1	1.8	22.8	1.9					43.1	1.7	43.2	1.7	26.0	
1996-1998	45.7	1.7	46.1	1.7	28.9	1.8	29.3	1.9					47.0	1.7	47.5	1.7	29.3	
1999-2001	44.5	1.6	44.9	1.7	28.3	1.7	28.9	1.8					46.9	1.6	47.3	1.7	29.2	
2002-2004	46.5	1.6	46.8	1.6	30.0	1.8	30.5	1.8					49.1	1.5	49.5	1.6	32.0	
2005-2007	48.2	1.9	48.6	1.9	31.3	2.2	31.9	2.2	21.1	2.5	21.3	2.6	50.4	1.9	50.8	1.9	33.0	
<b>ACUTE LYMPHATIC LEUKAEMIA</b>																		
1990-1992	26.1	4.7	26.1	4.7	21.4	4.5	21.4	4.5	20.3	4.5	20.3	4.5	22.8	5.4	22.8	5.4	18.7	
1993-1995	22.4	4.2	22.4	4.2	18.6	4.0	18.6	4.0					27.4	5.9	27.4	5.9	24.8	
1996-1998	24.9	4.7	24.9	4.7	21.8	4.5	22.0	4.5					23.6	5.6	23.3	5.6	22.0	
1999-2001	16.6	4.1	16.6	4.1									25.3	5.8	25.5	5.8		
2002-2004													37.4	6.3	37.6	6.3		
2005-2007													35.4	7.3	35.5	7.3		
<b>CHRONIC LYMPHATIC LEUKAEMIA</b>																		
1990-1992	66.7	2.7	67.0	2.7	40.5	3.1	40.8	3.1	25.7	3.0	25.9	3.2	71.1	2.8	71.7	2.8	55.4	
1993-1995	65.5	2.3	65.9	2.3	43.0	2.8	44.2	2.9					70.6	2.5	70.9	2.5	54.6	
1996-1998	69.8	2.2	70.5	2.2	46.7	2.7	48.3	2.9					75.5	2.0	76.3	2.1	59.4	
1999-2001	70.1	1.9	70.8	2.0	51.7	2.4	53.4	2.6					72.2	2.3	72.9	2.3	55.6	
2002-2004	68.7	2.1	69.1	2.1	49.4	2.5	50.8	2.6					75.0	2.0	75.6	2.0	58.9	
2005-2007	72.6	2.5	73.3	2.5	50.6	3.1	52.2	3.3	33.4	3.6	34.9	4.1	74.0	2.5	74.7	2.6	57.2	
<b>ACUTE MYELOID LEUKAEMIA</b>																		
1990-1992	7.8	1.4	7.9	1.4	5.8	1.2	5.8	1.2	4.7	1.1	4.8	1.1	9.5	1.5	9.7	1.6	8.1	
1993-1995	10.1	1.4	10.1	1.4	9.7	1.4	9.7	1.4					13.0	1.6	13.1	1.6	12.6	
1996-1998	12.1	1.5	12.2	1.5	10.6	1.4	10.5	1.4					12.7	1.7	12.7	1.7	10.5	
1999-2001	15.2	1.5	15.2	1.5									16.6	1.7	16.7	1.7	14.6	
2002-2004	13.6	1.4	13.6	1.4									16.7	1.7	16.9	1.7	14.2	
2005-2007	17.9	2.0	17.9	2.0									20.6	2.3	20.8	2.3	18.6	

Table 4. Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site.

CONTINUED OVERLEAF&gt;&gt;

Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

							MALE & FEMALE												
SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	
6.9	36.2	6.8	29.0	7.5	28.9	7.4	77.7	9.8	77.9	9.9	58.8	12.5	59.1	12.8	28.7	5.7	28.8	5.8	
13.3	60.1	13.0					91.0	9.1	92.3	9.4	81.0	16.2	78.1	14.5					
17.1	91.3	13.2					80.6	9.2	78.4	8.6	78.3	16.4	70.3	12.9					
9.1	76.3	10.0					89.8	5.7	90.8	5.9	81.3	8.7	82.5	9.2					
							75.0	6.8	76.5	7.0	64.5	8.1	65.8	8.6					
							81.0	8.5	82.5	8.7	65.3	10.9	68.1	12.0					
1.6	19.3	1.6	15.8	1.6	15.9	1.6	20.4	1.0	20.4	1.0	15.8	1.0	15.9	1.0	12.7	1.0	12.8	1.0	
1.5	17.3	1.5					21.5	1.0	21.5	1.0	16.0	1.0	16.1	1.0					
1.4	18.1	1.4					20.6	0.9	20.6	0.9	15.8	0.9	15.8	0.9					
1.5	19.4	1.5					22.6	1.0	22.7	1.0	17.1	0.9	17.1	0.9					
1.5	21.4	1.5					24.1	0.9	24.2	0.9	18.3	0.9	18.4	1.0					
2.0	22.0	2.0	20.1	2.0	20.1	2.0	23.5	1.2	23.5	1.2	17.9	1.2	18.0	1.2	15.6	1.2	15.8	1.2	
1.8	77.5	1.9	72.1	2.3	72.5	2.3	77.2	1.3	77.5	1.3	72.7	1.6	73.4	1.7	68.5	1.9	69.3	2.0	
1.5	81.7	1.6					82.1	1.1	82.5	1.1	78.1	1.4	78.9	1.4					
1.4	88.5	1.5					87.8	1.0	88.0	1.0	85.3	1.3	86.3	1.3					
1.2	89.4	1.3					90.1	0.8	90.6	0.8	87.1	1.1	88.2	1.2					
1.2	92.4	1.3					91.8	0.7	92.2	0.7	89.6	1.1	90.7	1.2					
1.5	97.3	1.6	90.0	3.6	91.7	4.2	94.9	0.7	95.2	0.8	93.9	1.4	95.1	1.5	89.2	3.3	91.5	3.9	
2.3	73.3	2.3	69.3	2.8	69.8	2.9	78.5	1.5	78.7	1.5	71.9	1.7	72.3	1.8	67.8	2.1	68.4	2.3	
2.1	74.4	2.2					78.4	1.6	78.5	1.6	71.7	1.8	71.7	1.8					
2.3	76.6	2.4					81.4	1.4	81.6	1.4	75.6	1.6	76.1	1.7					
2.2	81.9	2.3					83.1	1.3	83.4	1.3	76.5	1.6	77.0	1.7					
2.6	81.7	2.7					82.3	1.4	82.6	1.4	76.6	1.7	77.3	1.9					
3.0	84.9	3.1	76.7	2.8	76.9	2.9	81.2	1.6	81.5	1.6	74.6	1.9	75.1	2.1	69.9	1.8	70.1	1.9	
1.4	44.1	1.4	37.0	1.6	38.1	1.8	49.7	0.9	50.1	0.9	39.6	1.0	40.5	1.1	32.8	1.2	34.0	1.4	
1.3	44.8	1.3					51.3	0.8	51.8	0.9	41.7	1.0	42.5	1.0					
1.2	49.2	1.2					56.2	0.8	56.6	0.8	46.4	0.9	47.1	0.9					
1.2	52.7	1.3					58.6	0.7	59.1	0.8	49.5	0.9	50.6	0.9					
1.2	54.8	1.2					61.4	0.7	62.0	0.7	52.3	0.9	53.3	0.9					
1.5	59.2	1.6	47.9	2.1	49.3	2.3	64.3	0.9	64.9	0.9	54.9	1.1	56.1	1.2	44.5	1.7	45.9	1.9	
1.8	20.0	1.8	11.9	1.7	12.3	1.8	37.0	1.5	37.2	1.5	21.2	1.4	21.4	1.4	13.4	1.5	13.7	1.6	
1.7	26.2	1.7					41.1	1.3	41.4	1.3	24.1	1.2	24.5	1.3					
1.7	29.9	1.7					46.2	1.2	46.7	1.2	28.8	1.2	29.3	1.2					
1.6	29.7	1.7					45.5	1.2	45.9	1.2	28.5	1.2	29.1	1.2					
1.6	32.5	1.7					47.8	1.1	48.2	1.1	30.8	1.2	31.4	1.2					
1.9	33.5	2.0	24.0	2.2	24.5	2.3	49.3	1.3	49.7	1.4	32.3	1.4	32.8	1.5	22.4	1.7	22.9	1.7	
5.2	18.7	5.2	18.8	5.2	18.8	5.2	24.5	3.5	24.4	3.5	20.1	3.4	20.0	3.4	19.5	3.4	19.4	3.4	
5.8	24.8	5.8					24.3	3.4	24.3	3.4	20.9	3.3	20.9	3.3					
5.7	22.3	5.7					24.5	3.6	24.4	3.6	22.1	3.6	22.5	3.7					
							20.3	3.4	20.3	3.4									
							35.7	4.1	35.9	4.1									
							38.6	4.4	38.7	4.5									
3.3	56.2	3.4	42.0	3.8	42.7	4.0	68.7	1.9	69.1	1.9	47.2	2.3	48.0	2.4	33.3	2.5	34.3	2.7	
3.0	55.5	3.1					67.6	1.7	68.0	1.7	47.6	2.1	48.8	2.1					
2.7	61.0	2.8					72.0	1.5	72.8	1.5	51.8	1.9	53.5	2.0					
2.5	56.8	2.6					71.0	1.4	71.7	1.5	52.9	1.7	54.4	1.8					
2.3	59.9	2.4					71.0	1.5	71.5	1.5	52.6	1.7	53.9	1.8					
2.8	58.2	2.9	45.1	3.3	46.5	3.5	72.7	1.8	73.5	1.8	52.4	2.2	53.8	2.3	38.2	2.4	40.1	2.7	
1.5	8.6	1.6	8.5	1.9	9.7	2.5	8.7	1.0	8.9	1.1	7.1	1.0	7.4	1.1	6.9	1.2	8.0	1.7	
1.8	12.5	1.7					11.5	1.1	11.5	1.1	11.1	1.1	11.1	1.1					
1.6	10.6	1.6					12.3	1.1	12.3	1.1	10.5	1.1	10.6	1.1					
1.7	14.8	1.7					15.8	1.1	15.9	1.1	13.9	1.1	14.2	1.1					
1.7	14.3	1.7					15.0	1.1	15.1	1.1	13.0	1.1	13.3	1.1					
2.3	18.8	2.4					19.1	1.5	19.2	1.5	16.6	1.5	16.8	1.5					

**Table 4.** Five, 10,15-year age-standardized relative survival (5RS,10RS,15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE																	
Period	MALE												FEMALE				
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %
<b>CHRONIC MYELOID LEUKAEMIA</b>																	
1990-1992	35.3	3.5	35.5	3.5	12.3	2.5	12.4	2.5	7.4	1.9	7.6	2.0	35.9	3.6	36.3	3.7	16.6
1993-1995	30.1	2.8	30.2	2.8	16.8	2.3	16.7	2.3					37.7	3.5	38.1	3.6	18.5
1996-1998	34.7	2.8	34.7	2.8	22.8	2.6	22.9	2.6					40.6	3.6	40.9	3.6	31.7
1999-2001	45.7	3.1	46.2	3.1	37.3	3.6	37.9	3.7					47.7	3.4	48.2	3.5	39.2
2002-2004	44.4	3.1	44.4	3.1	36.2	3.6	36.6	3.7					53.5	3.3	53.8	3.3	45.0
2005-2007	55.8	3.9	56.1	3.9	43.6	4.7	44.7	5.0					58.5	3.8	58.7	3.9	49.2
<b>ALL LEUKAEMIAS</b>																	
1990-1992	38.4	1.5	38.5	1.5	24.3	1.5	24.3	1.5	17.5	1.5	17.6	1.6	36.7	1.6	37.0	1.6	25.8
1993-1995	39.1	1.3	39.4	1.3	27.9	1.4	28.6	1.5					38.2	1.4	38.6	1.4	28.3
1996-1998	42.8	1.3	43.3	1.3	30.7	1.4	31.6	1.5					43.8	1.4	44.1	1.4	34.6
1999-2001	45.5	1.2	46.0	1.2	34.6	1.3	35.7	1.4					43.2	1.4	43.6	1.4	33.6
2002-2004	43.8	1.2	44.0	1.2	33.9	1.3	34.7	1.3					44.2	1.4	44.5	1.4	35.4
2005-2007	47.4	1.5	47.9	1.5	36.2	1.6	37.2	1.7	26.4	1.9	27.6	2.2	44.1	1.7	44.5	1.7	35.2
<b>ALL BUT SKIN, NON MELANOMA</b>																	
1990-1992	38.6	0.2	38.8	0.2	32.0	0.3	32.4	0.3	27.6	0.4	28.2	0.4	53.0	0.2	53.4	0.2	46.2
1993-1995	42.3	0.2	42.5	0.2	35.7	0.3	36.2	0.3					55.1	0.2	55.5	0.2	48.0
1996-1998	46.8	0.2	47.1	0.2	39.7	0.2	40.4	0.3					58.2	0.2	58.7	0.2	51.6
1999-2001	50.7	0.2	51.0	0.2	43.7	0.2	44.4	0.3					59.8	0.2	60.4	0.2	53.2
2002-2004	54.6	0.2	55.0	0.2	47.5	0.2	48.2	0.3					61.1	0.2	61.7	0.2	54.7
2005-2007	57.3	0.2	57.8	0.2	49.9	0.3	50.7	0.3	44.2	0.5	45.1	0.6	62.6	0.2	63.2	0.2	56.0
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>																	
1990-1992	34.7	0.2	34.9	0.2	28.6	0.3	29.0	0.3	24.7	0.4	25.1	0.4	52.4	0.2	52.8	0.3	45.6
1993-1995	38.7	0.2	38.9	0.2	32.4	0.3	32.8	0.3					54.5	0.2	54.9	0.2	47.5
1996-1998	43.5	0.2	43.7	0.2	36.6	0.3	37.2	0.3					57.6	0.2	58.1	0.2	51.1
1999-2001	47.7	0.2	48.1	0.2	41.0	0.3	41.7	0.3					59.3	0.2	59.8	0.2	52.7
2002-2004	52.0	0.2	52.4	0.2	45.1	0.3	45.9	0.3					60.6	0.2	61.2	0.2	54.2
2005-2007	54.7	0.2	55.2	0.3	47.6	0.3	48.4	0.3	42.6	0.6	43.5	0.6	62.0	0.2	62.6	0.2	55.4

**Table 4.** Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CONTINUED OVERLEAF&gt;&gt;

							MALE & FEMALE												
SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	
3.2	17.2	3.5	6.5	1.9	6.4	1.9	35.3	2.6	35.5	2.6	14.2	2.0	14.4	2.1	6.9	1.3	6.9	1.4	
3.1	18.9	3.2					33.1	2.2	33.3	2.2	17.4	1.9	17.7	2.0					
3.5	32.4	3.7					36.8	2.2	37.1	2.2	26.0	2.1	26.6	2.2					
3.7	40.3	3.9					46.6	2.3	47.2	2.3	37.9	2.5	39.0	2.7					
3.9	46.0	4.1					48.6	2.3	48.8	2.3	39.9	2.6	40.9	2.8					
4.8	50.2	5.0					57.6	2.7	57.9	2.7	46.2	3.5	47.5	3.7					
1.6	26.2	1.6	19.9	1.7	20.3	1.8	37.8	1.1	37.9	1.1	25.2	1.1	25.4	1.1	18.8	1.1	19.3	1.2	
1.5	28.9	1.5					38.8	1.0	39.0	1.0	28.1	1.0	28.8	1.0					
1.5	35.4	1.5					43.2	0.9	43.6	1.0	32.3	1.0	33.2	1.0					
1.4	34.2	1.4					44.7	0.9	45.1	0.9	34.1	0.9	34.9	1.0					
1.4	36.0	1.4					43.9	0.9	44.2	0.9	34.3	0.9	35.0	1.0					
1.7	35.8	1.7	27.4	1.8	28.2	1.9	46.0	1.1	46.4	1.1	35.4	1.2	36.2	1.2	26.8	1.3	27.9	1.4	
0.3	47.0	0.3	41.8	0.4	42.9	0.4													
0.3	48.9	0.3																	
0.2	52.6	0.3																	
0.2	54.2	0.2																	
0.2	55.7	0.2																	
0.3	57.1	0.3	51.2	0.4	52.7	0.5													
0.3	46.3	0.3	41.2	0.4	42.3	0.4													
0.3	48.3	0.3																	
0.3	52.0	0.3																	
0.2	53.6	0.2																	
0.2	55.2	0.2																	
0.3	56.5	0.3	50.7	0.4	52.1	0.5													

**Table 4.** Five, 10, 15-year age-standardized relative survival (5RS, 10RS, 15RS) and standard error (SE) by period, gender and site. Pool of 11 cancer registries. [a] Ederer II method; [b] Hakulinen method

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%
<b>HEAD AND NECK</b>												
North-West	65.2	3.0	79.9	3.9	77.9	4.8	83.2	8.5	67.9	2.6	81.5	3.6
North-East	66.4	1.6	80.3	2.3	68.1	2.7	85.2	3.8	66.9	1.4	81.4	2.0
Centre	65.3	3.8	75.0	6.2	65.4	6.0	93.4	7.0	66.0	3.1	79.7	4.7
South	64.8	4.0	82.1	8.2	98.7	6.9	88.5	16.7	69.8	3.7	84.1	7.0
Pool	65.6	1.3	79.8	1.8	71.2	2.1	86.3	3.0	67.0	1.1	81.3	1.6
<b>SALIVARY GLANDS</b>												
North-West	72.2	12.2			81.3	10.5			77.4	9.2	74.7	13.8
North-East	53.0	6.6	92.4	8.1	95.1	5.6	94.9	11.6	68.3	5.2	88.6	5.8
Centre					72.1	5.7	103.2	0	75.7	7.3	100.9	7.2
South	87.4	23.0			112.8	9.0			90.8	14.5	127.1	12.4
Pool	61.8	4.7	95.4	5.0	82.3	5.9	91.3	6.8	70.6	3.7	89.5	4.1
<b>OESOPHAGUS</b>												
North-West												
North-East	33.9	4.3	83.2	11.8	38.0	7.1	80.4	11.6	36.4	3.8	79.7	8.9
Centre												
South												
Pool	32.4	3.6	95.0	9.9	38.7	6.0	92.1	7.5	33.9	3.1	84.8	8.2
<b>STOMACH</b>												
North-West	61.4	3.7	90.2	4.8	55.1	4.4	85.4	5.0	58.0	2.8	87.7	3.4
North-East	55.2	1.8	86.1	2.3	59.4	2.1	91.4	2.1	56.9	1.4	88.6	1.6
Centre	57.3	3.5	83.8	4.6	59.2	4.4	85.9	4.7	57.9	2.7	84.9	3.2
South	63.8	5.1	93.5	10.1	59.3	5.5	85.0	7.6	61.2	3.7	84.9	6.0
Pool	56.7	1.4	86.2	1.8	58.2	1.7	89.3	1.7	57.2	1.1	87.7	1.3
<b>SMALL INTESTINE</b>												
North-West												
North-East	62.9	5.9	85.9	8.6	73.7	6.2	105.0	5.2	70.6	3.9	96.5	5.1
Centre												
South									56.1	8.2		
Pool	65.0	4.7	88.4	7.1	68.5	4.7	99.4	4.5	67.5	3.2	94.7	4.2
<b>COLON</b>												
North-West	73.3	2.1	87.5	2.8	79.4	1.8	95.1	2.1	76.5	1.4	91.9	1.7
North-East	75.4	1.0	94.5	1.4	74.8	1.0	93.4	1.2	75.1	0.7	94.0	0.9
Centre	76.5	2.3	89.7	3.0	77.1	2.1	93.7	2.4	76.8	1.5	91.9	1.9
South	75.0	2.8	93.6	4.6	72.7	2.7	88.7	3.6	73.5	2.0	90.9	2.8
Pool	75.1	0.8	92.7	1.1	75.7	0.8	93.5	0.9	75.3	0.6	93.2	0.7
<b>RECTUM</b>												
North-West	68.0	2.9	83.2	4.9	66.0	2.7	89.8	3.4	66.2	2.0	86.4	2.8
North-East	73.9	1.5	91.0	2.4	71.1	1.6	87.9	2.0	72.5	1.1	88.7	1.5
Centre	74.3	2.9	85.6	4.1	73.6	3.1	92.4	4.1	74.0	2.2	88.7	3.0
South	65.1	3.6	87.3	5.8	59.4	4.0	83.9	5.4	61.9	2.7	85.4	4.1
Pool	71.7	1.2	88.1	1.8	69.1	1.2	88.2	1.5	70.4	0.9	87.9	1.2
<b>COLON RECTUM</b>												
North-West	71.5	1.7	85.7	2.4	75.2	1.6	93.5	1.8	73.2	1.2	90.1	1.5
North-East	74.9	0.9	93.1	1.2	73.8	0.9	92.0	1.0	74.3	0.6	92.4	0.8
Centre	75.6	1.8	88.6	2.4	75.8	1.8	93.2	2.1	75.7	1.3	90.9	1.6
South	70.8	2.2	91.2	3.6	67.7	2.3	86.5	3.1	69.2	1.6	88.9	2.3
Pool	73.9	0.7	91.1	1.0	73.7	0.7	91.9	0.8	73.7	0.5	91.5	0.6
<b>LIVER</b>												
North-West	37.1	3.5	56.1	6.4	29.8	5.4	61.8	10.9	33.5	3.5	45.9	6.8
North-East	29.3	2.2	53.2	6.1	29.7	3.6	53.3	8.9	29.4	1.8	53.9	4.8
Centre									29.5	5.3	45.4	12.1
South	28.6	3.9	59.6	13.0					25.7	3.1	45.2	8.0
Pool	30.6	1.6	54.7	4.1	27.4	2.7	44.5	7.2	29.7	1.4	51.9	3.2
<b>BILIARY TRACT</b>												
North-West												
North-East	41.3	5.9							40.4	4.1	84.2	5.9
Centre									40.8	6.5		
South	33.2	7.7	75.8	15.0								
Pool	38.4	3.7	88.2	6.5	41.3	4.0	85.5	4.4	39.6	2.7	85.2	4.0

Table 5. Conditional 5-year age-standardized relative survival, Ederer II method, after surviving 1, 5 years (5CS1, 5CS5) and standard error (SE) by gender and site. Pool of 21 cancer registries.

CONTINUED OVERLEAF&gt;&gt;



&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%
<b>PANCREAS</b>												
North-West					21.0	5.1	77.8	13.6	19.9	3.6	68.1	11.0
North-East	24.4	3.2	87.5	8.3	26.7	3.8	82.1	8.8	25.7	2.4	83.7	6.0
Centre					21.5	6.4			21.0	4.4	75.5	12.3
South	35.3	7.4							26.2	5.0	82.5	8.3
Pool	24.4	2.4	81.1	6.0	23.1	2.5	76.0	6.7	24.2	1.7	78.2	4.6
<b>LARYNX</b>												
North-West	76.9	3.6	89.3	5.1					77.6	3.4	88.7	4.7
North-East	75.6	2.2	84.1	2.9	75.8	5.4	80.0	6.8	76.1	2.0	83.6	2.6
Centre	75.8	4.7	72.2	7.6	74.4	14.6	102.4	16.8	73.7	4.7	74.8	6.8
South	76.7	5.2	96.3	9.0					78.4	5.0	92.7	8.6
Pool	75.5	1.7	84.0	2.3	75.8	4.3	79.0	5.4	75.9	1.6	83.4	2.1
<b>LUNG</b>												
North-West	29.1	2.2	67.7	4.9	35.5	3.4	78.7	6.5	31.1	1.8	69.8	3.8
North-East	33.4	1.4	72.6	2.8	37.8	1.9	74.4	3.5	34.9	1.1	72.7	2.2
Centre	30.3	2.4	86.4	5.1	38.9	4.1	72.4	7.3	32.7	2.1	79.7	4.3
South	28.4	2.8	76.2	6.2	40.2	4.5	62.5	9.5	31.9	2.3	74.9	5.1
Pool	31.6	1.0	73.0	2.1	37.7	1.4	74.7	2.7	33.5	0.8	73.2	1.6
<b>BONE</b>												
North-West					45.4	9.5			63.7	8.2		
North-East	59.7	7.7							61.6	6.3	93.3	6.4
Centre									69.3	6.3		
South												
Pool	64.5	5.2			65.4	5.0	94.8	3.8	65.5	4.0	96.6	3.9
<b>SKIN MELANOMA</b>												
North-West	87.9	2.5	96.6	2.8	89.9	2.1	96.0	2.1	88.4	1.7	96.7	1.7
North-East	87.4	1.5	95.9	2.0	91.9	1.1	96.8	1.4	89.7	0.9	96.3	1.2
Centre	88.2	2.9	93.0	4.4	87.0	2.8	92.0	3.2	87.4	2.0	91.9	2.7
South	77.1	4.2	95.5	5.0	86.1	3.7	96.8	4.0	82.2	2.8	95.7	3.3
Pool	86.8	1.1	95.5	1.5	90.5	0.9	96.0	1.1	88.6	0.7	95.7	0.9
<b>MESOTHELIOMA</b>												
North-West									11.0	3.8		
North-East	17.8	4.8							16.7	3.6		
Centre												
South												
Pool	12.0	2.6			17.3	4.9			13.0	2.2	42.5	9.8
<b>KAPOSI SARCOMA</b>												
North-West	93.6	7.0	95.4	4.5					89.5	5.9	94.3	5.5
North-East	98.8	5.5	89.9	6.0					99.6	4.1	94.2	6.3
Centre												
South												
Pool	100.5	4.1	92.5	5.3	86.0	6.1	98.7	4.7	96.8	3.1	95.1	4.3
<b>SOFT TISSUE</b>												
North-West	74.1	5.8	89.0	4.3	84.6	6.5	96.4	5.8	75.9	4.6	85.2	5.5
North-East	74.7	3.8	85.3	4.9	84.1	3.7	94.5	3.8	78.8	2.7	90.7	3.0
Centre	72.0	8.0			81.8	6.0	91.0	0	75.1	6.1	83.8	7.1
South	85.8	8.0	98.1	12.5	98.2	5.3	109.2	3.6	90.7	5.7	100.5	7.1
Pool	74.4	2.9	85.1	3.7	85.2	2.7	91.9	3.1	78.6	2.0	89.0	2.4
<b>BREAST</b>												
North-West					86.6	0.9	88.2	1.2				
North-East					87.7	0.5	90.0	0.7				
Centre					88.1	1.1	89.1	1.5				
South					85.9	1.4	82.5	2.0				
Pool					87.3	0.4	88.9	0.5				
<b>CERVIX UTERI</b>												
North-West					81.1	3.7	92.5	3.5				
North-East					77.6	2.0	92.3	1.9				
Centre					70.6	4.0	86.9	3.9				
South					73.1	4.3	90.4	4.0				
Pool					76.6	1.5	91.5	1.4				

Table 5. Conditional 5-year age-standardized relative survival, Ederer II method, after surviving 1, 5 years (5CS1, 5CS5) and standard error (SE) by gender and site. Pool of 21 cancer registries.

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%
<b>CORPUS UTERI</b>												
North-West					81.1	2.1	88.4	2.4				
North-East					83.8	1.2	92.4	1.6				
Centre					82.1	2.7	102.0	3.2				
South					73.3	3.0	86.6	4.3				
Pool					81.8	0.9	92.1	1.2				
<b>OVARY</b>												
North-West					52.6	3.0	74.7	4.4				
North-East					48.1	1.8	80.7	2.5				
Centre					53.1	3.8	85.0	6.4				
South					52.3	3.9	82.2	6.7				
Pool					50.3	1.4	80.4	1.9				
<b>PROSTATE</b>												
North-West	94.7	1.2	92.9	2.1								
North-East	92.2	0.6	90.6	1.0								
Centre	89.0	1.6	87.6	2.8								
South	87.8	1.9	78.9	4.1								
Pool	92.0	0.5	89.9	0.8								
<b>TESTIS</b>												
North-West	97.8	5.9										
North-East	96.9	3.0										
Centre	98.0	6.0										
South	105.3	4.6										
Pool	98.0	2.1	97.6	2.1								
<b>KIDNEY</b>												
North-West	83.7	3.2	86.6	5.0	86.0	3.2	93.7	3.7	83.4	2.3	88.6	3.2
North-East	81.5	1.6	85.5	2.4	82.7	1.7	91.3	2.0	81.8	1.2	88.4	1.6
Centre	86.1	3.2	94.8	4.5	80.8	3.5	89.1	5.6	83.3	2.4	92.7	3.5
South	85.1	3.7	84.1	4.7	84.7	5.6	82.4	8.2	85.9	3.6	83.6	5.0
Pool	82.9	1.3	86.8	1.9	82.7	1.4	90.8	1.7	82.6	0.9	88.6	1.3
<b>URINARY TRACT</b>												
North-West	80.8	7.4	106.7	9.7					77.7	5.6	104.2	6.6
North-East	71.4	4.1	83.9	5.7					72.4	3.4	85.5	4.0
Centre									85.6	7.8		
South												
Pool	74.9	3.2	87.8	4.3					74.9	2.6	89.2	3.2
<b>URINARY BLADDER</b>												
North-West	85.9	1.5	85.5	2.1	91.1	2.8	97.4	3.2	87.0	1.3	89.0	1.8
North-East	85.1	0.9	87.8	1.2	87.1	1.4	90.8	1.7	85.3	0.7	88.3	1.0
Centre	80.6	1.7	86.1	2.3	85.0	3.4	101.3	3.4	81.5	1.5	88.6	2.0
South	82.3	1.8	89.8	2.6	85.2	3.6	94.7	4.5	82.7	1.6	90.9	2.2
Pool	84.3	0.6	87.4	0.9	87.7	1.1	94.1	1.3	84.8	0.6	88.8	0.8
<b>CHOROID MELANOMA</b>												
North-West												
North-East					54.7	0	95.5	0	66.1	9.8	89.7	6.0
Centre												
South												
Pool	85.0	12.0	88.6	18.4					81.3	8.5	83.7	9.6
<b>BRAIN AND CENTRAL NERVOUS SYSTEM</b>												
North-West					42.4	6.8			33.3	4.1		
North-East	34.0	3.0	76.8	5.3	49.2	4.1	73.8	6.1	39.6	2.4	75.8	4.0
Centre					43.6	8.5			37.0	4.6	84.8	5.9
South	39.4	5.5			56.2	7.3	97.7	5.5	45.3	4.7	86.9	6.2
Pool	33.4	2.1	75.0	3.7	47.9	2.9	77.6	3.9	39.0	1.7	76.3	2.7
<b>THYROID</b>												
North-West	96.1	3.8	98.1	4.4	96.1	2.2	95.5	3.5	96.0	1.9	96.0	2.8
North-East	94.9	2.0	94.4	3.5	100.0	0.8	98.8	1.5	98.6	0.8	97.9	1.4
Centre	95.8	4.6	104.6	6.1	98.5	2.2	99.5	3.9	97.6	2.0	100.2	3.5
South	93.2	5.2	87.1	7.7	98.2	2.3	100.9	3.8	96.0	2.2	97.6	4.0
Pool	94.7	1.6	95.3	2.8	99.1	0.7	98.7	1.2	97.9	0.7	98.1	1.1

Table 5. Conditional 5-year age-standardized relative survival, Ederer II method, after surviving 1, 5 years (5CS1, 5CS5) and standard error (SE) by gender and site. Pool of 21 cancer registries.

CONTINUED OVERLEAF&gt;&gt;

&gt;&gt; CONTINUED FROM OVERLEAF

CANCER SITE												
Macroarea	MALE				FEMALE				MALE & FEMALE			
	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%
<b>HODGKIN LYMPHOMA</b>												
North-West									84.2	3.9		
North-East	85.6	2.1			91.7	2.2	95.6	2.2	88.7	1.6	94.4	1.6
Centre												
South	87.8	2.4			95.0	4.8			90.6	2.7		
Pool	85.4	1.4	93.1	1.2	91.4	1.8	94.8	2.1	88.0	1.2	92.7	1.2
<b>NON HODGKIN LYMPHOMA</b>												
North-West	76.0	2.7	81.3	3.8	82.8	2.4	85.7	3.0	79.8	1.8	83.3	2.4
North-East	80.7	1.7	86.9	2.4	83.6	1.4	84.9	2.0	81.9	1.1	86.0	1.5
Centre	74.3	4.1	67.3	5.6	81.6	3.2	94.7	4.2	77.7	2.6	81.5	4.2
South	75.6	4.1	106.2	8.0	72.4	3.8	84.8	4.5	73.5	2.8	92.8	4.0
Pool	78.4	1.3	84.6	1.9	82.4	1.1	85.8	1.5	80.1	0.8	85.2	1.2
<b>MYELOMA</b>												
North-West	47.3	5.0	66.5	11.2	53.2	4.8	63.3	7.6	48.8	3.8	55.3	7.1
North-East	56.7	2.7	65.8	3.4	59.0	2.6	68.7	3.4	58.2	1.8	68.0	2.4
Centre	60.2	5.5	48.1	10.7	56.3	5.3			56.9	4.1	54.6	6.3
South	49.9	7.4	59.0	12.7	45.2	6.3	48.8	9.0	49.2	4.5	60.1	6.7
Pool	54.3	2.1	62.3	3.2	55.8	2.0	65.1	2.7	55.4	1.4	64.1	2.1
<b>ACUTE LYMPHATIC LEUKAEMIA</b>												
North-West												
North-East					48.0	12.6			53.8	7.7		
Centre												
South												
Pool					53.5	9.1			56.1	5.8		
<b>CHRONIC LYMPHATIC LEUKAEMIA</b>												
North-West									78.2	3.3	71.4	4.0
North-East	72.2	3.2	70.6	3.7	81.6	3.0	79.3	3.0	75.0	2.3	73.2	2.4
Centre												
South												
Pool	72.0	2.4	69.4	3.0	79.0	2.3	78.7	2.4	74.6	1.7	72.8	2.0
<b>ACUTE MYELOID LEUKAEMIA</b>												
North-West												
North-East	49.9	5.0			44.8	5.7			47.8	3.7		
Centre												
South												
Pool	42.8	3.6			47.0	4.0	92.8	4.7	44.3	2.6	91.2	3.1
<b>CHRONIC MYELOID LEUKAEMIA</b>												
North-West	49.9	9.3			54.4	10.0	102.9	7.3	55.5	6.3	80.9	9.6
North-East	72.6	5.4	77.4	8.1	75.7	5.3	73.7	8.9	74.8	3.5	77.7	5.9
Centre	68.9	14.5			76.3	8.8	97.8	8.8	68.2	10.8	72.5	14.1
South	69.2	9.3			85.6	12.3			74.1	7.7	90.6	9.6
Pool	67.1	4.2	74.9	6.3	73.2	3.7	85.8	5.2	70.5	2.8	79.1	4.3
<b>ALL LEUKAEMIAS</b>												
North-West	68.6	3.9	73.5	4.9	62.1	4.4	82.9	4.6	66.3	2.9	78.5	3.3
North-East	67.0	2.2	74.2	2.8	69.0	2.6	80.2	2.7	68.0	1.7	75.8	1.9
Centre	53.3	4.9	78.1	7.6	68.0	4.9	76.4	6.6	60.4	3.5	76.5	4.7
South	62.5	4.6	73.2	6.2	61.0	5.0	88.0	5.8	61.4	3.4	78.3	4.2
Pool	65.1	1.7	74.6	2.1	67.0	1.9	81.3	2.0	65.9	1.2	77.0	1.5
<b>ALL BUT SKIN, NON MELANOMA</b>												
North-West	75.1	0.6	86.1	0.8	76.9	0.5	89.0	0.7				
North-East	75.5	0.3	87.7	0.5	78.0	0.3	89.8	0.4				
Centre	72.9	0.7	85.7	1.0	77.4	0.6	90.0	0.8				
South	70.5	0.8	85.9	1.4	74.5	0.8	85.6	1.0				
Pool	74.5	0.2	87.0	0.4	77.4	0.2	89.3	0.3				
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>												
North-West	73.5	0.6	86.3	0.9	76.4	0.6	88.6	0.7				
North-East	74.2	0.3	87.7	0.5	77.7	0.3	89.8	0.4				
Centre	71.9	0.7	85.7	1.1	77.1	0.6	89.6	0.8				
South	68.2	0.9	84.7	1.6	74.2	0.8	85.1	1.0				
Pool	73.2	0.3	86.9	0.4	77.0	0.2	89.1	0.3				

**Table 5.** Conditional 5-year age-standardized relative survival, Ederer II method, after surviving 1, 5 years (5CS1, 5CS5) and standard error (SE) by gender and site. Pool of 21 cancer registries.

CANCER SITE								
Macroarea	MALE				FEMALE			
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>ALL BUT SKIN, NON MELANOMA</b>								
North-West	52.5	0.2	52.8	0.2	60.7	0.2	61.1	0.2
North-East	52.3	0.2	52.6	0.2	61.0	0.2	61.4	0.2
Centre	51.2	0.3	51.5	0.3	61.5	0.3	61.9	0.3
South	48.5	0.3	48.8	0.3	56.9	0.3	57.1	0.3
Pool	51.9	0.1	52.2	0.1	60.4	0.1	60.8	0.1
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>								
North-West	49.4	0.2	49.8	0.2	60.2	0.2	60.5	0.2
North-East	49.2	0.2	49.5	0.2	60.4	0.2	60.7	0.2
Centre	48.1	0.3	48.4	0.3	60.8	0.3	61.2	0.3
South	45.2	0.3	45.5	0.3	56.4	0.3	56.7	0.3
Pool	48.8	0.1	49.1	0.2	59.8	0.1	60.2	0.1

Table 6a. All cases adjusted for case mix. Five-year age-standardized relative survival (5RS) and standard error (SE) by macroarea and gender. Pool of 31 cancer registries, 2000-2004. [a] Ederer II method; [b] Hakulinen method

CANCER SITE																								
Macroarea	MALE												FEMALE											
	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	5RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	5RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	10RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	10RS <sup>[b]</sup> %	SE <sup>[b]</sup> %	15RS <sup>[a]</sup> %	SE <sup>[a]</sup> %	15RS <sup>[b]</sup> %	SE <sup>[b]</sup> %
<b>ALL BUT SKIN, NON MELANOMA</b>																								
1990-1992	41.3	0.5	41.5	0.5	34.0	0.5	34.5	0.5	29.5	0.6	30.3	0.6	54.2	0.3	54.6	0.3	47.2	0.3	47.8	0.3	42.5	0.4	43.5	0.4
1993-1995	44.8	0.3	45.0	0.3	37.5	0.4	38.1	0.4					55.9	0.2	56.2	0.2	48.7	0.3	49.4	0.3				
1996-1998	48.6	0.3	48.9	0.3	41.4	0.3	42.1	0.3					58.7	0.2	59.1	0.2	52.1	0.3	52.8	0.3				
1999-2001	50.7	0.3	51.0	0.3	43.7	0.3	44.4	0.3					59.8	0.2	60.3	0.2	53.0	0.3	53.9	0.3				
2002-2004	52.5	0.3	52.8	0.3	45.5	0.3	46.2	0.3					61.2	0.2	61.6	0.2	54.5	0.3	55.4	0.3				
2005-2007	54.6	0.3	55.0	0.3	47.5	0.4	48.2	0.4					62.7	0.2	63.1	0.2	55.9	0.3	56.8	0.3				
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>																								
1990-1992	37.8	0.5	38.0	0.5	30.9	0.5	31.4	0.5	26.7	0.6	27.4	0.6	53.4	0.3	53.7	0.3	46.3	0.3	47.0	0.3	41.7	0.4	42.6	0.4
1993-1995	41.5	0.4	41.7	0.4	34.4	0.4	35.0	0.4					55.2	0.2	55.5	0.2	48.0	0.3	48.7	0.3				
1996-1998	45.4	0.3	45.7	0.3	38.5	0.4	39.1	0.4					58.1	0.2	58.4	0.2	51.4	0.3	52.1	0.3				
1999-2001	47.6	0.3	48.0	0.3	40.9	0.4	41.6	0.4					59.1	0.2	59.6	0.2	52.3	0.3	53.2	0.3				
2002-2004	49.4	0.3	49.7	0.3	42.7	0.3	43.4	0.3					60.5	0.2	61.0	0.2	53.8	0.3	54.7	0.3				
2005-2007	51.7	0.4	52.1	0.4	45.0	0.4	45.7	0.4					62.0	0.2	62.4	0.2	55.1	0.3	56.0	0.3				

Table 6b. All cases adjusted for case mix. Five, 10, 15-year age-standardized relative survival (RS) and standard error (SE) by period and gender. Pool of 11 cancer registries [a] Ederer II method; [b] Hakulinen method

CANCER SITE								
Macroarea	MALE				FEMALE			
	5CS1%	SE%	5CS5%	SE%	5CS1%	SE%	5CS5%	SE%
<b>ALL BUT SKIN, NON MELANOMA</b>								
Pool	72.5	0.4	86.7	0.5	76.7	0.2	88.9	0.3
<b>ALL BUT BLADDER AND SKIN, NON MELANOMA</b>								
Pool	70.8	0.4	86.7	0.5	76.3	0.2	88.6	0.3

Table 6c. All cases adjusted for case mix. Conditional 5-year age-standardized relative survival, Ederer II method, after surviving 1, 5 years (5CS1, 5CS5) and standard error (SE) by gender. Pool of 21 cancer registries.